{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:49Z","timestamp":1790912509745,"version":"4.1.0"},"reference-count":329,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82304062"],"award-info":[{"award-number":["82304062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2024NSFSC1626"],"award-info":[{"award-number":["2024NSFSC1626"]}]},{"name":"the Postdoctoral Fund of Sichuan University","award":["2023SCU12065"],"award-info":[{"award-number":["2023SCU12065"]}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024HXBH182"],"award-info":[{"award-number":["2024HXBH182"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017939","name":"Sichuan\u00a0Provincial\u00a0Postdoctoral\u00a0Science Foundation","doi-asserted-by":"publisher","award":["2024M752267"],"award-info":[{"award-number":["2024M752267"]}],"id":[{"id":"10.13039\/100017939","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Achievement Transformation Demonstration Project of the Key research and development (R&D) Program of Science & Technology Department of Chengdu","award":["2023-YF09-00003-SN"],"award-info":[{"award-number":["2023-YF09-00003-SN"]}]},{"name":"the Postdoctoral Research Fund of West China Hospital, Sichuan University","award":["2023HXBH098"],"award-info":[{"award-number":["2023HXBH098"]}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1551"],"award-info":[{"award-number":["2023NSFSC1551"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Autoimmune bullous diseases (AIBDs) represent a heterogeneous group of immune-mediated disorders characterized by life-threatening blistering of the skin and mucous membranes. This Review synthesizes current understanding of AIBD pathogenesis, clinical phenotypes, diagnostic approaches, and therapeutic strategies, emphasizing recent advancements and translational opportunities. At the core of AIBDs is autoantibody-mediated disruption of structural proteins in the epidermis or basement membrane zone, particularly at desmosomal and hemidesmosomal junctions. Key subtypes, including pemphigus, paraneoplastic pemphigus, pemphigoid, and IgA-related diseases, are distinguished by their target antigens, clinical manifestations, and immunopathological profiles. Diagnostic workflows rely on direct immunofluorescence, and serological assays, yet subtype differentiation remains challenging due to overlapping features. Traditional therapies, such as systemic corticosteroids and immunosuppressants, have improved outcomes but are limited by toxicity. Recent breakthroughs highlight targeted interventions, including B-cell depletion with rituximab, cytokine modulation via dupilumab, and JAK inhibitors for inflammatory pathways. Innovative strategies like chimeric autoantibody receptor T-cell (CAART) therapy further address refractory cases by eliminating autoreactive B cells. Additionally, the Review underscores the emerging role of inflammation-driven mechanisms and the necessity of multidisciplinary care, given AIBDs\u2019 associations with malignancies, autoimmune comorbidities. Despite progress, challenges persist in early diagnosis, personalized therapy optimization, and understanding antigen-specific immune responses. Future directions include refining diagnostic biomarkers, exploring novel targets, and developing precision medicine approaches.<\/jats:p>","DOI":"10.1186\/s43556-025-00272-9","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:17:35Z","timestamp":1747300655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Autoimmune bullous diseases: pathogenesis and clinical management"],"prefix":"10.1186","volume":"6","author":[{"given":"Xun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-2884","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"9479","key":"272_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","volume":"366","author":"JC Bystryn","year":"2005","unstructured":"Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366(9479):61\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(05)66829-8.","journal-title":"Lancet"},{"issue":"9863","key":"272_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4.","journal-title":"Lancet"},{"issue":"2","key":"272_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0738-081x(83)90019-6","volume":"1","author":"DF King","year":"1983","unstructured":"King DF, Holubar K. History of pemphigus. Clin Dermatol. 1983;1(2):6\u201312. https:\/\/doi.org\/10.1016\/0738-081x(83)90019-6.","journal-title":"Clin Dermatol."},{"issue":"1","key":"272_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","volume":"32","author":"WF Lever","year":"1953","unstructured":"Lever WF. Pemphigus. Medicine (Baltimore). 1953;32(1):1\u201323. https:\/\/doi.org\/10.1097\/00005792-195302000-00001.","journal-title":"Medicine (Baltimore)."},{"key":"272_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3181\/00379727-117-29622","volume":"117","author":"EH Beutner","year":"1964","unstructured":"Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117:505\u201310. https:\/\/doi.org\/10.3181\/00379727-117-29622.","journal-title":"Proc Soc Exp Biol Med."},{"issue":"20","key":"272_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM197005142822011","volume":"282","author":"KA Arndt","year":"1970","unstructured":"Arndt KA, Feingold DS. The sign of Pyotr Vasilyewich Nikolsky. N Engl J Med. 1970;282(20):1154\u20135. https:\/\/doi.org\/10.1056\/NEJM197005142822011.","journal-title":"N Engl J Med"},{"issue":"5 Pt 1","key":"272_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0190-9622(87)80419-x","volume":"16","author":"CW Doubleday","year":"1987","unstructured":"Doubleday CW. Who is Nikolsky and what does his sign mean? J Am Acad Dermatol. 1987;16(5 Pt 1):1054\u20135. https:\/\/doi.org\/10.1016\/s0190-9622(87)80419-x.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"272_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/1523-1747.ep12259692","volume":"82","author":"WR Gammon","year":"1984","unstructured":"Gammon WR, Briggaman RA, Inman AO 3rd, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol. 1984;82(2):139\u201344. https:\/\/doi.org\/10.1111\/1523-1747.ep12259692.","journal-title":"J Invest Dermatol."},{"issue":"11","key":"272_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1610-0387.2011.07809.x","volume":"9","author":"A Kneisel","year":"2011","unstructured":"Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011;9(11):927\u201347. https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07809.x.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"3\u20134","key":"272_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","volume":"52","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wang Y, Chen X, Jin H, Li L. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med. 2020;52(3\u20134):55\u201362. https:\/\/doi.org\/10.1080\/07853890.2020.1742367.","journal-title":"Ann Med"},{"issue":"5","key":"272_CR11","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.4317\/jced.56289","volume":"12","author":"Z Delavarian","year":"2020","unstructured":"Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent. 2020;12(5):e440\u20135. https:\/\/doi.org\/10.4317\/jced.56289.","journal-title":"J Clin Exp Dent"},{"issue":"4\u20135","key":"272_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","volume":"13","author":"S Baum","year":"2014","unstructured":"Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev. 2014;13(4\u20135):482\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.047.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"272_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/15665240113136660079","volume":"14","author":"JV Otten","year":"2014","unstructured":"Otten JV, Hashimoto T, Hertl M, Payne AS, Sitaru C. Molecular diagnosis in autoimmune skin blistering conditions. Curr Mol Med. 2014;14(1):69\u201395. https:\/\/doi.org\/10.2174\/15665240113136660079.","journal-title":"Curr Mol Med"},{"issue":"2","key":"272_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","volume":"10","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10(2):84\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2010.08.007.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"272_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2020.11.076","volume":"85","author":"CM Montagnon","year":"2021","unstructured":"Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Subepithelial autoimmune blistering dermatoses: clinical features and diagnosis. J Am Acad Dermatol. 2021;85(1):1\u201314. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.076.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"272_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/LBR.0000000000000374","volume":"24","author":"BA Jalil","year":"2017","unstructured":"Jalil BA, Abdou YG, Rosen SA, Dammad T. Mucous membrane pemphigoid causing central airway obstruction. J Bronchology Interv Pulmonol. 2017;24(4):334\u20138. https:\/\/doi.org\/10.1097\/LBR.0000000000000374.","journal-title":"J Bronchology Interv Pulmonol"},{"issue":"4","key":"272_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.oooo.2013.12.402","volume":"117","author":"T Hayakawa","year":"2014","unstructured":"Hayakawa T, Furumura M, Fukano H, Li X, Ishii N, Hamada T, et al. Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(4):483\u201396. https:\/\/doi.org\/10.1016\/j.oooo.2013.12.402.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"272_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jdv.13397","volume":"30","author":"KT Amber","year":"2016","unstructured":"Amber KT, Bloom R, Hertl M. A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA. J Eur Acad Dermatol Venereol. 2016;30(1):72\u20137. https:\/\/doi.org\/10.1111\/jdv.13397.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"272_CR19","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/sj.jid.5700465","volume":"126","author":"KA Rashid","year":"2006","unstructured":"Rashid KA, Gurcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol. 2006;126(12):2631\u20136. https:\/\/doi.org\/10.1038\/sj.jid.5700465.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"272_CR20","first-page":"2283","volume":"40","author":"RY Chan","year":"1999","unstructured":"Chan RY, Bhol K, Tesavibul N, Letko E, Simmons RK, Foster CS, et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1999;40(10):2283\u201390.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"272_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.clim.2004.04.010","volume":"112","author":"SW Yeh","year":"2004","unstructured":"Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol. 2004;112(3):268\u201372. https:\/\/doi.org\/10.1016\/j.clim.2004.04.010.","journal-title":"Clin Immunol"},{"issue":"4","key":"272_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","volume":"29","author":"P Joly","year":"2011","unstructured":"Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29(4):432\u20136. https:\/\/doi.org\/10.1016\/j.clindermatol.2011.01.013.","journal-title":"Clin Dermatol"},{"issue":"4","key":"272_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/biom13040703","volume":"13","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Qian H, Ishii N, Nakama T, Tateishi C, Tsuruta D, et al. Classification and antigen molecules of autoimmune bullous diseases. Biomolecules. 2023;13(4):703. https:\/\/doi.org\/10.3390\/biom13040703.","journal-title":"Biomolecules."},{"issue":"4","key":"272_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000530121","volume":"239","author":"L Zhao","year":"2023","unstructured":"Zhao L, Chen Y, Wang M. The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis. Dermatology. 2023;239(4):514\u201322. https:\/\/doi.org\/10.1159\/000530121.","journal-title":"Dermatology"},{"issue":"12","key":"272_CR25","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F Hubner","year":"2016","unstructured":"Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol. 2016;136(12):2495\u20138. https:\/\/doi.org\/10.1016\/j.jid.2016.07.013.","journal-title":"J Invest Dermatol"},{"issue":"5\u20136","key":"272_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00403-007-0760-y","volume":"299","author":"JD Torzecka","year":"2007","unstructured":"Torzecka JD, Wozniak K, Kowalewski C, Waszczykowska E, Sysa-Jedrzejowska A, Pas HH, et al. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? Arch Dermatol Res. 2007;299(5\u20136):239\u201343. https:\/\/doi.org\/10.1007\/s00403-007-0760-y.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"272_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.17191","volume":"180","author":"SY Zhang","year":"2019","unstructured":"Zhang SY, Zhou XY, Zhou XL, Zhang Y, Deng Y, Liao F, et al. Subtype-specific inherited predisposition to pemphigus in the Chinese population. Br J Dermatol. 2019;180(4):828\u201335. https:\/\/doi.org\/10.1111\/bjd.17191.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2133.2012.11040.x","volume":"167","author":"L Yan","year":"2012","unstructured":"Yan L, Wang JM, Zeng K. Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: a meta-analysis. Br J Dermatol. 2012;167(4):768\u201377. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11040.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-4632.2005.02038.x","volume":"44","author":"S-d-O del Mar","year":"2005","unstructured":"del Mar S-d-O, Vega-Memije ME, Zuniga J, Salgado N, Ruiz J, Balbuena A, et al. HLA-DRB1*0101 is associated with foliaceous pemphigus in Mexicans. Int J Dermatol. 2005;44(4):350. https:\/\/doi.org\/10.1111\/j.1365-4632.2005.02038.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"272_CR30","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1111\/bjd.16022","volume":"178","author":"L de Sena Nogueira Maehara","year":"2018","unstructured":"de Sena Nogueira Maehara L, De-Souza-Santana FC, Porro AM, Marcos EVC, Ura S, Nolte IM, et al. HLA class II alleles of susceptibility and protection in Brazilian and Dutch pemphigus foliaceus. Br J Dermatol. 2018;178(3):e212\u20134. https:\/\/doi.org\/10.1111\/bjd.16022.","journal-title":"Br J Dermatol."},{"issue":"1","key":"272_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1523-1747.1999.00626.x","volume":"113","author":"ML Lombardi","year":"1999","unstructured":"Lombardi ML, Mercuro O, Ruocco V, Lo Schiavo A, Lombari V, Guerrera V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol. 1999;113(1):107\u201310. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00626.x.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/jaut.2000.0388","volume":"15","author":"P Loiseau","year":"2000","unstructured":"Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15(1):67\u201373. https:\/\/doi.org\/10.1006\/jaut.2000.0388.","journal-title":"J Autoimmun"},{"issue":"1","key":"272_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/1346-8138.12675","volume":"42","author":"V Aoki","year":"2015","unstructured":"Aoki V, Rivitti EA, Diaz LA, Cooperative Group on Fogo Selvagem R. Update on fogo selvagem, an endemic form of pemphigus foliaceus. J Dermatol. 2015;42(1):18\u201326. https:\/\/doi.org\/10.1111\/1346-8138.12675.","journal-title":"J Dermatol."},{"issue":"3","key":"272_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1365-2133.2009.09207.x","volume":"161","author":"O Abida","year":"2009","unstructured":"Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol. 2009;161(3):522\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09207.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"272_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00403-017-1790-8","volume":"310","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2017;310(2):95\u2013106. https:\/\/doi.org\/10.1007\/s00403-017-1790-8.","journal-title":"Arch Dermatol Res"},{"issue":"3\u20134","key":"272_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1473-2130.2004.00098.x","volume":"2","author":"S Brenner","year":"2003","unstructured":"Brenner S, Srebrnik A, Goldberg I. Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols. J Cosmet Dermatol. 2003;2(3\u20134):161\u20135. https:\/\/doi.org\/10.1111\/j.1473-2130.2004.00098.x.","journal-title":"J Cosmet Dermatol"},{"key":"272_CR37","doi-asserted-by":"publisher","first-page":"1058759","DOI":"10.3389\/fimmu.2022.1058759","volume":"13","author":"OT Adebiyi","year":"2022","unstructured":"Adebiyi OT, Galloway DF, Augustin MS, Sinha AA. The multifactorial complexities of autoimmune development in Pemphigus vulgaris: critical evaluation of the role of environmental and lifestyle \u201cexposome\u201d factors. Front Immunol. 2022;13:1058759. https:\/\/doi.org\/10.3389\/fimmu.2022.1058759.","journal-title":"Front Immunol"},{"issue":"6","key":"272_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1684\/ejd.2012.1836","volume":"22","author":"P Senger","year":"2012","unstructured":"Senger P, Sinha AA. Exploring the link between herpes viruses and pemphigus vulgaris: literature review and commentary. Eur J Dermatol. 2012;22(6):728\u201335. https:\/\/doi.org\/10.1684\/ejd.2012.1836.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"272_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/eci.10.94","volume":"7","author":"G Caldarola","year":"2011","unstructured":"Caldarola G, Feliciani C. A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris? Expert Rev Clin Immunol. 2011;7(2):187\u201391. https:\/\/doi.org\/10.1586\/eci.10.94.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"272_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/s0190-9622(89)70079-7","volume":"20","author":"LA Diaz","year":"1989","unstructured":"Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989;20(4):657\u201369. https:\/\/doi.org\/10.1016\/s0190-9622(89)70079-7.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"272_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1067\/s0190-9622(03)00851-x","volume":"49","author":"AM Abreu-Velez","year":"2003","unstructured":"Abreu-Velez AM, Hashimoto T, Bollag WB, Tobon Arroyave S, Abreu-Velez CE, Londono ML, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003;49(4):599\u2013608. https:\/\/doi.org\/10.1067\/s0190-9622(03)00851-x.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"272_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1046\/j.1365-2133.1996.d01-745.x","volume":"134","author":"A Mahe","year":"1996","unstructured":"Mahe A, Flageul B, Cisse I, Keita S, Bobin P. Pemphigus in Mali: a study of 30 cases. Br J Dermatol. 1996;134(1):114\u20139.","journal-title":"Br J Dermatol."},{"issue":"3","key":"272_CR43","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","volume":"135","author":"CM Hammers","year":"2015","unstructured":"Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, et al. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2015;135(3):742\u20139. https:\/\/doi.org\/10.1038\/jid.2014.291.","journal-title":"J Invest Dermatol"},{"key":"272_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","volume":"30","author":"C Mauri","year":"2012","unstructured":"Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221\u201341. https:\/\/doi.org\/10.1146\/annurev-immunol-020711-074934.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"272_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI119130","volume":"99","author":"MS Lin","year":"1997","unstructured":"Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest. 1997;99(1):31\u201340. https:\/\/doi.org\/10.1172\/JCI119130.","journal-title":"J Clin Invest"},{"issue":"5","key":"272_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2230.2005.01836.x","volume":"30","author":"C Rizzo","year":"2005","unstructured":"Rizzo C, Fotino M, Zhang Y, Chow S, Spizuoco A, Sinha AA. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol. 2005;30(5):535\u201340. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01836.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"272_CR47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","volume":"38","author":"A Satyam","year":"2009","unstructured":"Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest. 2009;38(6):498\u2013509. https:\/\/doi.org\/10.1080\/08820130902943097.","journal-title":"Immunol Invest"},{"issue":"1","key":"272_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4049\/jimmunol.170.1.635","volume":"170","author":"C Veldman","year":"2003","unstructured":"Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003;170(1):635\u201342. https:\/\/doi.org\/10.4049\/jimmunol.170.1.635.","journal-title":"J Immunol"},{"issue":"10","key":"272_CR49","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.imbio.2015.06.008","volume":"220","author":"R Asothai","year":"2015","unstructured":"Asothai R, Anand V, Das D, Antil PS, Khandpur S, Sharma VK, et al. Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17\/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. Immunobiology. 2015;220(10):1129\u201335. https:\/\/doi.org\/10.1016\/j.imbio.2015.06.008.","journal-title":"Immunobiology"},{"issue":"6","key":"272_CR50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1684\/ejd.2013.2177","volume":"23","author":"RC Xu","year":"2013","unstructured":"Xu RC, Zhu HQ, Li WP, Zhao XQ, Yuan HJ, Zheng J, et al. The imbalance of Th17 and regulatory T cells in pemphigus patients. Eur J Dermatol. 2013;23(6):795\u2013802. https:\/\/doi.org\/10.1684\/ejd.2013.2177.","journal-title":"Eur J Dermatol"},{"issue":"11","key":"272_CR51","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.jid.2017.05.032","volume":"137","author":"H Yuan","year":"2017","unstructured":"Yuan H, Zhou S, Liu Z, Cong W, Fei X, Zeng W, et al. Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis. J Invest Dermatol. 2017;137(11):2362\u201370. https:\/\/doi.org\/10.1016\/j.jid.2017.05.032.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"272_CR52","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.4049\/jimmunol.172.10.6468","volume":"172","author":"C Veldman","year":"2004","unstructured":"Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004;172(10):6468\u201375. https:\/\/doi.org\/10.4049\/jimmunol.172.10.6468.","journal-title":"J Immunol"},{"issue":"5","key":"272_CR53","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.4049\/jimmunol.176.5.3215","volume":"176","author":"C Veldman","year":"2006","unstructured":"Veldman C, Pahl A, Beissert S, Hansen W, Buer J, Dieckmann D, et al. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. J Immunol. 2006;176(5):3215\u201322. https:\/\/doi.org\/10.4049\/jimmunol.176.5.3215.","journal-title":"J Immunol"},{"issue":"3","key":"272_CR54","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1468-3083.2008.03035.x","volume":"23","author":"M Alecu","year":"2009","unstructured":"Alecu M, Ursaciuc C, Surcel M, Coman G, Ciotaru D, Dobre M. CD28 T-cell costimulatory molecule expression in pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2009;23(3):288\u201391. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.03035.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"272_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0625.2006.00522.x","volume":"16","author":"A Rensing-Ehl","year":"2007","unstructured":"Rensing-Ehl A, Gaus B, Bruckner-Tuderman L, Martin SF. Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Exp Dermatol. 2007;16(1):13\u201321. https:\/\/doi.org\/10.1111\/j.1600-0625.2006.00522.x.","journal-title":"Exp Dermatol"},{"issue":"1","key":"272_CR56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-011-9597-4","volume":"32","author":"H Zhu","year":"2012","unstructured":"Zhu H, Chen Y, Zhou Y, Wang Y, Zheng J, Pan M. Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris. J Clin Immunol. 2012;32(1):114\u201323. https:\/\/doi.org\/10.1007\/s10875-011-9597-4.","journal-title":"J Clin Immunol"},{"issue":"2","key":"272_CR57","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0192623311430693","volume":"40","author":"RA Peterson","year":"2012","unstructured":"Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol. 2012;40(2):186\u2013204. https:\/\/doi.org\/10.1177\/0192623311430693.","journal-title":"Toxicol Pathol"},{"issue":"2","key":"272_CR58","doi-asserted-by":"publisher","first-page":"e0148919","DOI":"10.1371\/journal.pone.0148919","volume":"11","author":"T Hennerici","year":"2016","unstructured":"Hennerici T, Pollmann R, Schmidt T, Seipelt M, Tackenberg B, Mobs C, et al. Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus. PLoS ONE. 2016;11(2):e0148919. https:\/\/doi.org\/10.1371\/journal.pone.0148919.","journal-title":"PLoS ONE"},{"issue":"5","key":"272_CR59","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/bjd.15113","volume":"176","author":"M Kabuto","year":"2017","unstructured":"Kabuto M, Fujimoto N, Takahashi T, Tanaka T. Decreased level of interleukin-10-producing B cells in patients with pemphigus but not in patients with pemphigoid. Br J Dermatol. 2017;176(5):1204\u201312. https:\/\/doi.org\/10.1111\/bjd.15113.","journal-title":"Br J Dermatol"},{"issue":"1","key":"272_CR60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjd.13192","volume":"172","author":"HQ Zhu","year":"2015","unstructured":"Zhu HQ, Xu RC, Chen YY, Yuan HJ, Cao H, Zhao XQ, et al. Impaired function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus. Br J Dermatol. 2015;172(1):101\u201310. https:\/\/doi.org\/10.1111\/bjd.13192.","journal-title":"Br J Dermatol"},{"issue":"2","key":"272_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jid.2019.07.717","volume":"140","author":"S Zhou","year":"2020","unstructured":"Zhou S, Liu Z, Yuan H, Zhao X, Zou Y, Zheng J, et al. Autoreactive B cell differentiation in diffuse ectopic lymphoid-like structures of inflamed pemphigus lesions. J Invest Dermatol. 2020;140(2):309\u2013318 e8. https:\/\/doi.org\/10.1016\/j.jid.2019.07.717.","journal-title":"J Invest Dermatol."},{"issue":"10","key":"272_CR62","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jid.2023.03.1661","volume":"143","author":"S Egami","year":"2023","unstructured":"Egami S, Watanabe T, Fukushima-Nomura A, Nomura H, Takahashi H, Yamagami J, et al. Desmoglein-specific B-cell-targeted single-cell analysis revealing unique gene regulation in patients with pemphigus. J Invest Dermatol. 2023;143(10):1919\u20131928 e16. https:\/\/doi.org\/10.1016\/j.jid.2023.03.1661.","journal-title":"J Invest Dermatol."},{"key":"272_CR63","doi-asserted-by":"publisher","first-page":"110219","DOI":"10.1016\/j.clim.2024.110219","volume":"263","author":"Z Hu","year":"2024","unstructured":"Hu Z, Zheng M, Guo Z, Zhou W, Zhou W, Yao N, et al. Single-cell sequencing reveals distinct immune cell features in cutaneous lesions of pemphigus vulgaris and bullous pemphigoid. Clin Immunol. 2024;263:110219. https:\/\/doi.org\/10.1016\/j.clim.2024.110219.","journal-title":"Clin Immunol"},{"issue":"3","key":"272_CR64","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.2300312","volume":"212","author":"S Duan","year":"2024","unstructured":"Duan S, Li Q, Wang F, Kuang W, Dong Y, Liu D, et al. Single-cell transcriptomes and immune repertoires reveal the cell state and molecular changes in pemphigus vulgaris. J Immunol. 2024;212(3):375\u201388. https:\/\/doi.org\/10.4049\/jimmunol.2300312.","journal-title":"J Immunol"},{"key":"272_CR65","doi-asserted-by":"publisher","first-page":"103128","DOI":"10.1016\/j.jaut.2023.103128","volume":"142","author":"C Xu","year":"2024","unstructured":"Xu C, Zhang T, Wang H, Zhu L, Ruan Y, Huang Z, et al. Integrative single-cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus. J Autoimmun. 2024;142:103128. https:\/\/doi.org\/10.1016\/j.jaut.2023.103128.","journal-title":"J Autoimmun"},{"issue":"23","key":"272_CR66","doi-asserted-by":"publisher","first-page":"e166357","DOI":"10.1172\/JCI166357","volume":"133","author":"D Han","year":"2023","unstructured":"Han D, Lee AY, Kim T, Choi JY, Cho MY, Song A, et al. Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters. J Clin Invest. 2023;133(23):e166357. https:\/\/doi.org\/10.1172\/JCI166357.","journal-title":"J Clin Invest."},{"issue":"10","key":"272_CR67","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jid.2024.03.016","volume":"144","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhao S, Zhang X, Xia D, Xiao Y, Zhou X, et al. Single-cell transcriptome analysis reveals interaction between CCL19+ inflammatory keratinocytes and CCR7+ dendritic cells and B cells in pemphigus. J Invest Dermatol. 2024;144(10):2301\u20132305 e8. https:\/\/doi.org\/10.1016\/j.jid.2024.03.016.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"272_CR68","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000051540","volume":"201","author":"SA Grando","year":"2000","unstructured":"Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology. 2000;201(4):290\u20135. https:\/\/doi.org\/10.1159\/000051540.","journal-title":"Dermatology"},{"issue":"4","key":"272_CR69","first-page":"307","volume":"65","author":"F Pitoia","year":"2005","unstructured":"Pitoia F, Moncet D, Glorio R, Graciela Diaz A, Rodriguez Costa G, Carbia S, et al. Prevalence of thyroid autoimmunity in patients with pemphigus vulgaris. Medicina (B Aires). 2005;65(4):307\u201310.","journal-title":"Medicina (B Aires)"},{"issue":"4","key":"272_CR70","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1046\/j.0022-202x.2001.01489.x","volume":"117","author":"SA Grando","year":"2001","unstructured":"Grando SA, Pittelkow MR, Shultz LD, Dmochowski M, Nguyen VT. Pemphigus: an unfolding story. J Invest Dermatol. 2001;117(4):990\u20135. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01489.x.","journal-title":"J Invest Dermatol"},{"issue":"44","key":"272_CR71","doi-asserted-by":"publisher","first-page":"30556","DOI":"10.1074\/jbc.M109.024810","volume":"284","author":"V Spindler","year":"2009","unstructured":"Spindler V, Heupel WM, Efthymiadis A, Schmidt E, Eming R, Rankl C, et al. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus. J Biol Chem. 2009;284(44):30556\u201364. https:\/\/doi.org\/10.1074\/jbc.M109.024810.","journal-title":"J Biol Chem"},{"issue":"4","key":"272_CR72","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/s0002-9440(10)64651-2","volume":"157","author":"VT Nguyen","year":"2000","unstructured":"Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol. 2000;157(4):1377\u201391. https:\/\/doi.org\/10.1016\/s0002-9440(10)64651-2.","journal-title":"Am J Pathol"},{"issue":"2","key":"272_CR73","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ajpath.2011.04.015","volume":"179","author":"K Tsunoda","year":"2011","unstructured":"Tsunoda K, Ota T, Saito M, Hata T, Shimizu A, Ishiko A, et al. Pathogenic relevance of IgG and IgM antibodies against desmoglein 3 in blister formation in pemphigus vulgaris. Am J Pathol. 2011;179(2):795\u2013806. https:\/\/doi.org\/10.1016\/j.ajpath.2011.04.015.","journal-title":"Am J Pathol"},{"key":"272_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","volume":"11","author":"CM Hammers","year":"2016","unstructured":"Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11:175\u201397. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044313.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"272_CR75","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/0955-0674(94)90094-9","volume":"6","author":"PJ Koch","year":"1994","unstructured":"Koch PJ, Franke WW. Desmosomal cadherins: another growing multigene family of adhesion molecules. Curr Opin Cell Biol. 1994;6(5):682\u20137. https:\/\/doi.org\/10.1016\/0955-0674(94)90094-9.","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"272_CR76","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1046\/j.1523-1747.2003.12113.x","volume":"120","author":"NV Whittock","year":"2003","unstructured":"Whittock NV, Bower C. Genetic evidence for a novel human desmosomal cadherin, desmoglein 4. J Invest Dermatol. 2003;120(4):523\u201330. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12113.x.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"272_CR77","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/sj.jid.5701015","volume":"127","author":"KJ Green","year":"2007","unstructured":"Green KJ, Simpson CL. Desmosomes: new perspectives on a classic. J Invest Dermatol. 2007;127(11):2499\u2013515. https:\/\/doi.org\/10.1038\/sj.jid.5701015.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"272_CR78","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1523-1747.ep12316680","volume":"105","author":"AP Kowalczyk","year":"1995","unstructured":"Kowalczyk AP, Anderson JE, Borgwardt JE, Hashimoto T, Stanley JR, Green KJ. Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol. 1995;105(2):147\u201352. https:\/\/doi.org\/10.1111\/1523-1747.ep12316680.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0923-1811(00)00113-4","volume":"25","author":"Y Ohata","year":"2001","unstructured":"Ohata Y, Amagai M, Ishii K, Hashimoto T. Immunoreactivity against intracellular domains of desmogleins in pemphigus. J Dermatol Sci. 2001;25(1):64\u201371. https:\/\/doi.org\/10.1016\/s0923-1811(00)00113-4.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"272_CR80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/psc.2476","volume":"19","author":"H Szabados","year":"2013","unstructured":"Szabados H, Bosze S, Sillo P, Karpati S, Hudecz F, Uray K. The mapping of linear B-cell epitope regions in the extracellular parts of the desmoglein 1 and 3 proteins: recognition of immobilized peptides by pemphigus patients\u2019 serum autoantibodies. J Pept Sci. 2013;19(2):84\u201394. https:\/\/doi.org\/10.1002\/psc.2476.","journal-title":"J Pept Sci"},{"issue":"9","key":"272_CR81","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.4049\/jimmunol.167.9.5439","volume":"167","author":"M Sekiguchi","year":"2001","unstructured":"Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol. 2001;167(9):5439\u201348. https:\/\/doi.org\/10.4049\/jimmunol.167.9.5439.","journal-title":"J Immunol"},{"issue":"4","key":"272_CR82","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1365-2230.2003.01311.x","volume":"28","author":"NV Whittock","year":"2003","unstructured":"Whittock NV, Bower C. Targetting of desmoglein 1 in inherited and acquired skin diseases. Clin Exp Dermatol. 2003;28(4):410\u20135. https:\/\/doi.org\/10.1046\/j.1365-2230.2003.01311.x.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"272_CR83","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1365-2133.2012.10827.x","volume":"166","author":"H Koga","year":"2012","unstructured":"Koga H, Ohyama B, Tsuruta D, Ishii N, Hamada T, Dainichi T, et al. Five Japanese cases of antidesmoglein 1 antibody-positive and antidesmoglein 3 antibody-negative pemphigus with oral lesions. Br J Dermatol. 2012;166(5):976\u201380. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10827.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"272_CR84","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1365-2133.2010.09696.x","volume":"162","author":"PT Chan","year":"2010","unstructured":"Chan PT, Ohyama B, Nishifuji K, Yoshida K, Ishii K, Hashimoto T, et al. Immune response towards the amino-terminus of desmoglein 1 prevails across different activity stages in nonendemic pemphigus foliaceus. Br J Dermatol. 2010;162(6):1242\u201350. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09696.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"272_CR85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1684\/ejd.2014.2277","volume":"24","author":"A Espana","year":"2014","unstructured":"Espana A, Koga H, Suarez-Fernandez R, Ohata C, Ishii N, Irarrazaval I, et al. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus. Eur J Dermatol. 2014;24(2):174\u20139. https:\/\/doi.org\/10.1684\/ejd.2014.2277.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"272_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjd.14098","volume":"174","author":"K Kamiya","year":"2016","unstructured":"Kamiya K, Aoyama Y, Yamasaki O, Kamata A, Yamagami J, Iwatsuki K, et al. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages. Br J Dermatol. 2016;174(1):113\u20139. https:\/\/doi.org\/10.1111\/bjd.14098.","journal-title":"Br J Dermatol"},{"issue":"6","key":"272_CR87","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.0022-202X.2004.23438.x","volume":"123","author":"LA Diaz","year":"2004","unstructured":"Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, et al. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. J Invest Dermatol. 2004;123(6):1045\u201351. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23438.x.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdermsci.2013.02.002","volume":"70","author":"A Toumi","year":"2013","unstructured":"Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, et al. Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci. 2013;70(1):19\u201325. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.02.002.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"272_CR89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1006\/clim.2002.5259","volume":"105","author":"MK Hacker","year":"2002","unstructured":"Hacker MK, Janson M, Fairley JA, Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol. 2002;105(1):64\u201374. https:\/\/doi.org\/10.1006\/clim.2002.5259.","journal-title":"Clin Immunol"},{"issue":"6","key":"272_CR90","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s0190-9622(03)02160-1","volume":"49","author":"Y Futei","year":"2003","unstructured":"Futei Y, Amagai M, Hashimoto T, Nishikawa T. Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol. 2003;49(6):1023\u20138. https:\/\/doi.org\/10.1016\/s0190-9622(03)02160-1.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"272_CR91","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2230.2009.03525.x","volume":"35","author":"S Lebeau","year":"2010","unstructured":"Lebeau S, Muller R, Masouye I, Hertl M, Borradori L. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol. 2010;35(4):366\u201372. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03525.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"272_CR92","doi-asserted-by":"publisher","first-page":"e0156800","DOI":"10.1371\/journal.pone.0156800","volume":"11","author":"AS Lo","year":"2016","unstructured":"Lo AS, Mao X, Mukherjee EM, Ellebrecht CT, Yu X, Posner MR, et al. Pathogenicity and epitope characteristics do not differ in IgG subclass-switched anti-desmoglein 3 IgG1 and IgG4 autoantibodies in pemphigus vulgaris. PLoS ONE. 2016;11(6):e0156800. https:\/\/doi.org\/10.1371\/journal.pone.0156800.","journal-title":"PLoS ONE"},{"key":"272_CR93","doi-asserted-by":"publisher","first-page":"1163066","DOI":"10.3389\/fimmu.2023.1163066","volume":"14","author":"T Schmitt","year":"2023","unstructured":"Schmitt T, Hudemann C, Moztarzadeh S, Hertl M, Tikkanen R, Waschke J. Dsg3 epitope-specific signalling in pemphigus. Front Immunol. 2023;14:1163066. https:\/\/doi.org\/10.3389\/fimmu.2023.1163066.","journal-title":"Front Immunol"},{"issue":"17","key":"272_CR94","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMra061111","volume":"355","author":"JR Stanley","year":"2006","unstructured":"Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355(17):1800\u201310. https:\/\/doi.org\/10.1056\/NEJMra061111.","journal-title":"N Engl J Med"},{"issue":"2","key":"272_CR95","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1067\/mjd.2003.7","volume":"48","author":"M Amagai","year":"2003","unstructured":"Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol. 2003;48(2):244\u201352. https:\/\/doi.org\/10.1067\/mjd.2003.7.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"272_CR96","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1582-4934.2007.00033.x","volume":"11","author":"S Mihai","year":"2007","unstructured":"Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med. 2007;11(3):462\u201381. https:\/\/doi.org\/10.1111\/j.1582-4934.2007.00033.x.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"272_CR97","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","volume":"159","author":"K Ishii","year":"1997","unstructured":"Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159(4):2010\u20137.","journal-title":"J Immunol"},{"issue":"9","key":"272_CR98","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","volume":"34","author":"P Joly","year":"2020","unstructured":"Joly P, Horvath B, Patsatsi A, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900\u201313. https:\/\/doi.org\/10.1111\/jdv.16752.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"272_CR99","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.xjidi.2021.100004","volume":"1","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innov. 2021;1(1):100004. https:\/\/doi.org\/10.1016\/j.xjidi.2021.100004.","journal-title":"JID Innov"},{"issue":"3","key":"272_CR100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","volume":"61","author":"W Zhao","year":"2021","unstructured":"Zhao W, Wang J, Zhu H, Pan M. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies. Clin Rev Allergy Immunol. 2021;61(3):351\u201362. https:\/\/doi.org\/10.1007\/s12016-021-08882-1.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"272_CR101","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.14405","volume":"175","author":"C Boulard","year":"2016","unstructured":"Boulard C, Duvert Lehembre S, Picard-Dahan C, Kern JS, Zambruno G, Feliciani C, et al. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175(1):142\u20139. https:\/\/doi.org\/10.1111\/bjd.14405.","journal-title":"Br J Dermatol"},{"issue":"6","key":"272_CR102","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2008.01.012.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"272_CR103","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1346-8138.16265","volume":"49","author":"X Zhou","year":"2022","unstructured":"Zhou X, Cheng L, Wang Y, Gou H, Ju K, Lan T, et al. Effect of NUDT15 polymorphisms on early hematological safety of low-dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study. J Dermatol. 2022;49(4):402\u201310. https:\/\/doi.org\/10.1111\/1346-8138.16265.","journal-title":"J Dermatol"},{"issue":"6","key":"272_CR104","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jdv.16188","volume":"34","author":"R Kakuta","year":"2020","unstructured":"Kakuta R, Kurihara Y, Yamagami J, Miyamoto J, Funakoshi T, Tanikawa A, et al. Results of the guideline-based treatment for pemphigus: a single-centre experience with 84 cases. J Eur Acad Dermatol Venereol. 2020;34(6):1324\u201330. https:\/\/doi.org\/10.1111\/jdv.16188.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"272_CR105","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/1346-8138.16653","volume":"50","author":"J Yamagami","year":"2023","unstructured":"Yamagami J. B-cell targeted therapy of pemphigus. J Dermatol. 2023;50(2):124\u201331. https:\/\/doi.org\/10.1111\/1346-8138.16653.","journal-title":"J Dermatol"},{"issue":"Suppl 2","key":"272_CR106","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","volume":"13","author":"T Cerny","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(Suppl 2):S3\u201310. https:\/\/doi.org\/10.1097\/00001813-200211002-00002.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"272_CR107","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1067\/mjd.2002.126273","volume":"47","author":"TG Salopek","year":"2002","unstructured":"Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47(5):785\u20138. https:\/\/doi.org\/10.1067\/mjd.2002.126273.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"272_CR108","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau JC, D\u2019Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545\u201352. https:\/\/doi.org\/10.1056\/NEJMoa067752.","journal-title":"N Engl J Med"},{"issue":"8","key":"272_CR109","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","volume":"95","author":"HH Wang","year":"2015","unstructured":"Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928\u201332. https:\/\/doi.org\/10.2340\/00015555-2116.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"272_CR110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","volume":"79","author":"MA Saleh","year":"2018","unstructured":"Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79(1):97\u2013103. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.029.","journal-title":"J Am Acad Dermatol"},{"issue":"10083","key":"272_CR111","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(17)30070-3.","journal-title":"Lancet"},{"issue":"1","key":"272_CR112","doi-asserted-by":"publisher","first-page":"2302071","DOI":"10.1080\/09546634.2024.2302071","volume":"35","author":"X Zhou","year":"2024","unstructured":"Zhou X, Zhan T, Xu X, Lan T, Hu H, Zhou Y, et al. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study. J Dermatolog Treat. 2024;35(1):2302071. https:\/\/doi.org\/10.1080\/09546634.2024.2302071.","journal-title":"J Dermatolog Treat"},{"key":"272_CR113","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64. https:\/\/doi.org\/10.1186\/1756-8722-5-64.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"272_CR114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"FH Du","year":"2017","unstructured":"Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. https:\/\/doi.org\/10.1007\/s13317-017-0100-y.","journal-title":"Auto Immun Highlights"},{"issue":"12","key":"272_CR115","first-page":"1338","volume":"17","author":"M Rapp","year":"2018","unstructured":"Rapp M, Pentland A, Richardson C. Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol. 2018;17(12):1338\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"272_CR116","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/1346-8138.17108","volume":"51","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xiao Y, Li X, Wang J, Zhou X, Wang Y, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab. J Dermatol. 2024;51(7):1026\u201330. https:\/\/doi.org\/10.1111\/1346-8138.17108.","journal-title":"J Dermatol"},{"key":"272_CR117","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20245","author":"J Mao","year":"2024","unstructured":"Mao J, Bao S, Chen Y, Zhuang Z, Chen W, Li G, et al. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi-centre cohort study. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20245.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"272_CR118","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","volume":"150","author":"CT Ellebrecht","year":"2014","unstructured":"Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150(12):1331\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2014.1939.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"272_CR119","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/all.15261","volume":"77","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Brasileiro A, Kolkhir P, Frischbutter S, Scheffel J, Monino-Romero S, et al. Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355\u201366. https:\/\/doi.org\/10.1111\/all.15261.","journal-title":"Allergy"},{"issue":"4","key":"272_CR120","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.20431","volume":"185","author":"DF Murrell","year":"2021","unstructured":"Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol. 2021;185(4):745\u201355. https:\/\/doi.org\/10.1111\/bjd.20431.","journal-title":"Br J Dermatol"},{"issue":"8","key":"272_CR121","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","volume":"144","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, et al. Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study. J Invest Dermatol. 2024;144(8):1762\u20131771 e6. https:\/\/doi.org\/10.1016\/j.jid.2024.02.023.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"272_CR122","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399. https:\/\/doi.org\/10.1038\/s41573-020-00092-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"272_CR123","doi-asserted-by":"publisher","first-page":"e16679","DOI":"10.1016\/j.heliyon.2023.e16679","volume":"9","author":"K Abulikemu","year":"2023","unstructured":"Abulikemu K, Hu F, Liang J, Kang X. Targeting therapy in pemphigus: where are we now and where are we going? Heliyon. 2023;9(6):e16679. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16679.","journal-title":"Heliyon"},{"issue":"12","key":"272_CR124","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/j.jid.2021.06.035","volume":"141","author":"CA Nelson","year":"2021","unstructured":"Nelson CA, Tomayko MM. Targeting the FcRn: a novel approach to the treatment of pemphigus. J Invest Dermatol. 2021;141(12):2777\u201380. https:\/\/doi.org\/10.1016\/j.jid.2021.06.035.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"272_CR125","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Csorgo Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186(3):429\u201339. https:\/\/doi.org\/10.1111\/bjd.20782.","journal-title":"Br J Dermatol"},{"issue":"12","key":"272_CR126","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130(12):6317\u201324. https:\/\/doi.org\/10.1172\/JCI138416.","journal-title":"J Clin Invest"},{"issue":"9","key":"272_CR127","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.jid.2021.01.030","volume":"141","author":"Y Zou","year":"2021","unstructured":"Zou Y, Yuan H, Zhou S, Zhou Y, Zheng J, Zhu H, et al. The pathogenic role of CD4(+) tissue-resident memory T cells bearing T follicular helper-like phenotype in pemphigus lesions. J Invest Dermatol. 2021;141(9):2141\u201350. https:\/\/doi.org\/10.1016\/j.jid.2021.01.030.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"272_CR128","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2340\/00015555-2706","volume":"97","author":"K Kridin","year":"2017","unstructured":"Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Acta Derm Venereol. 2017;97(9):1095\u20139. https:\/\/doi.org\/10.2340\/00015555-2706.","journal-title":"Acta Derm Venereol"},{"key":"272_CR129","doi-asserted-by":"publisher","first-page":"112307","DOI":"10.1016\/j.intimp.2024.112307","volume":"135","author":"X Feng","year":"2024","unstructured":"Feng X, Zhou X, Zhang X, Xiao Y, Li F, Mi W, et al. Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: a single-center survey-based study. Int Immunopharmacol. 2024;135:112307. https:\/\/doi.org\/10.1016\/j.intimp.2024.112307.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"272_CR130","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41415-024-7074-8","volume":"236","author":"G Davis","year":"2024","unstructured":"Davis G, Hathway R, Shipley D, Staines K. The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review. Br Dent J. 2024;236(4):311\u20136. https:\/\/doi.org\/10.1038\/s41415-024-7074-8.","journal-title":"Br Dent J"},{"issue":"4","key":"272_CR131","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/15360288.2021.1963906","volume":"35","author":"A Dominguez-Franco","year":"2021","unstructured":"Dominguez-Franco A, Mendez-Flores S, Ramirez-Marin HA, Olvera-Rodriguez V, Dominguez-Cherit JG. Pain management in patients with severe pemphigus vulgaris. J Pain Palliat Care Pharmacother. 2021;35(4):278\u201382. https:\/\/doi.org\/10.1080\/15360288.2021.1963906.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"2","key":"272_CR132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/ICL.0000000000000155","volume":"42","author":"P Chirinos-Saldana","year":"2016","unstructured":"Chirinos-Saldana P, Navas A, Ramirez-Miranda A, Jimenez-Martinez MC, Graue-Hernandez EO. Pemphigus: an ophthalmological review. Eye Contact Lens. 2016;42(2):91\u20138. https:\/\/doi.org\/10.1097\/ICL.0000000000000155.","journal-title":"Eye Contact Lens"},{"key":"272_CR133","doi-asserted-by":"publisher","first-page":"bcr2013200479","DOI":"10.1136\/bcr-2013-200479","volume":"2013","author":"C Vinall","year":"2013","unstructured":"Vinall C, Stevens L, McArdle P. Pemphigus vulgaris: a multidisciplinary approach to management. BMJ Case Rep. 2013;2013:bcr2013200479. https:\/\/doi.org\/10.1136\/bcr-2013-200479.","journal-title":"BMJ Case Rep."},{"issue":"44","key":"272_CR134","first-page":"3127","volume":"98","author":"JR Prakken","year":"1954","unstructured":"Prakken JR, Woerdeman MJ. Paraneoplastic pemphigus and pemphigus vulgaris. Ned Tijdschr Geneeskd. 1954;98(44):3127\u201335.","journal-title":"Ned Tijdschr Geneeskd."},{"issue":"2","key":"272_CR135","first-page":"193","volume":"137","author":"VT Nguyen","year":"2001","unstructured":"Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137(2):193\u2013206.\u00a0https:\/\/doi.org\/10.1001\/pubs.ArchDermatol-ISSN-0003-987x-137-2-dob00057.","journal-title":"Arch Dermatol"},{"issue":"25","key":"272_CR136","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","volume":"323","author":"GJ Anhalt","year":"1990","unstructured":"Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729\u201335. https:\/\/doi.org\/10.1056\/NEJM199012203232503.","journal-title":"N Engl J Med."},{"issue":"6","key":"272_CR137","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/jdv.18931","volume":"37","author":"E Antiga","year":"2023","unstructured":"Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, et al. S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023;37(6):1118\u201334. https:\/\/doi.org\/10.1111\/jdv.18931.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"272_CR138","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0896-8411(02)00092-6","volume":"20","author":"P Martel","year":"2003","unstructured":"Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun. 2003;20(1):91\u20135. https:\/\/doi.org\/10.1016\/s0896-8411(02)00092-6.","journal-title":"J Autoimmun"},{"issue":"3","key":"272_CR139","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08361.x","volume":"158","author":"Q Liu","year":"2008","unstructured":"Liu Q, Bu DF, Li D, Zhu XJ. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol. 2008;158(3):587\u201391. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08361.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"272_CR140","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1523-1747.ep12336235","volume":"109","author":"SC Kim","year":"1997","unstructured":"Kim SC, Kwon YD, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol. 1997;109(3):365\u20139. https:\/\/doi.org\/10.1111\/1523-1747.ep12336235.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"272_CR141","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1523-1747.1998.00279.x","volume":"111","author":"MG Mahoney","year":"1998","unstructured":"Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. 1998;111(2):308\u201313. https:\/\/doi.org\/10.1046\/j.1523-1747.1998.00279.x.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"272_CR142","doi-asserted-by":"publisher","first-page":"e12250","DOI":"10.1371\/journal.pone.0012250","volume":"5","author":"I Schepens","year":"2010","unstructured":"Schepens I, Jaunin F, Begre N, Laderach U, Marcus K, Hashimoto T, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS ONE. 2010;5(8):e12250. https:\/\/doi.org\/10.1371\/journal.pone.0012250.","journal-title":"PLoS ONE"},{"issue":"4","key":"272_CR143","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.jid.5700198","volume":"126","author":"B Zhang","year":"2006","unstructured":"Zhang B, Zheng R, Wang J, Bu D, Zhu X. Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J Invest Dermatol. 2006;126(4):832\u201340. https:\/\/doi.org\/10.1038\/sj.jid.5700198.","journal-title":"J Invest Dermatol"},{"issue":"9408","key":"272_CR144","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(04)15539-6","volume":"363","author":"L Wang","year":"2004","unstructured":"Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman\u2019s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363(9408):525\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(04)15539-6.","journal-title":"Lancet"},{"issue":"3","key":"272_CR145","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2005.06599.x","volume":"153","author":"J Wang","year":"2005","unstructured":"Wang J, Bu DF, Li T, Zheng R, Zhang BX, Chen XX, et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol. 2005;153(3):558\u201364. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06599.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"272_CR146","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/archderm.136.5.652","volume":"136","author":"GM Bowen","year":"2000","unstructured":"Bowen GM, Peters NT, Fivenson DP, Su LD, Nousari HC, Anhalt GJ, et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol. 2000;136(5):652\u20136. https:\/\/doi.org\/10.1001\/archderm.136.5.652.","journal-title":"Arch Dermatol"},{"issue":"5","key":"272_CR147","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/bjd.15389","volume":"176","author":"K Okahashi","year":"2017","unstructured":"Okahashi K, Oiso N, Ishii N, Miyake M, Uchida S, Matsuda H, et al. Paraneoplastic pemphigus associated with Castleman disease: progression from mucous to mucocutaneous lesions with epitope-spreading phenomena. Br J Dermatol. 2017;176(5):1406\u20139. https:\/\/doi.org\/10.1111\/bjd.15389.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR148","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1365-2133.1999.03123.x","volume":"141","author":"K Reich","year":"1999","unstructured":"Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol. 1999;141(4):739\u201346. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.03123.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"272_CR149","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1083\/jcb.134.3.715","volume":"134","author":"C Ruhrberg","year":"1996","unstructured":"Ruhrberg C, Hajibagheri MA, Simon M, Dooley TP, Watt FM. Envoplakin, a novel precursor of the cornified envelope that has homology to desmoplakin. J Cell Biol. 1996;134(3):715\u201329. https:\/\/doi.org\/10.1083\/jcb.134.3.715.","journal-title":"J Cell Biol"},{"issue":"7","key":"272_CR150","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1083\/jcb.139.7.1835","volume":"139","author":"C Ruhrberg","year":"1997","unstructured":"Ruhrberg C, Hajibagheri MA, Parry DA, Watt FM. Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin. J Cell Biol. 1997;139(7):1835\u201349. https:\/\/doi.org\/10.1083\/jcb.139.7.1835.","journal-title":"J Cell Biol"},{"issue":"3","key":"272_CR151","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0141-8130(05)80004-2","volume":"14","author":"KJ Green","year":"1992","unstructured":"Green KJ, Virata ML, Elgart GW, Stanley JR, Parry DA. Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: members of a new gene family involved in organization of intermediate filaments. Int J Biol Macromol. 1992;14(3):145\u201353. https:\/\/doi.org\/10.1016\/s0141-8130(05)80004-2.","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"272_CR152","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00403-008-0901-y","volume":"301","author":"Y Huang","year":"2009","unstructured":"Huang Y, Li J, Zhu X. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus. Arch Dermatol Res. 2009;301(10):703\u20139. https:\/\/doi.org\/10.1007\/s00403-008-0901-y.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"272_CR153","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.clim.2008.07.021","volume":"129","author":"H Mouquet","year":"2008","unstructured":"Mouquet H, Drenovska K, Lartigue A, Joly P, Drouot L, Thomas M, et al. Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay. Clin Immunol. 2008;129(2):304\u201312. https:\/\/doi.org\/10.1016\/j.clim.2008.07.021.","journal-title":"Clin Immunol"},{"issue":"1","key":"272_CR154","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdermsci.2016.06.011","volume":"84","author":"X Wang","year":"2016","unstructured":"Wang X, Chen T, Zhao J, Peng Y, Chen X, Tu P, et al. Extremities of the N-terminus of envoplakin and C-terminus of its linker subdomain are major epitopes of paraneoplastic pemphigus. J Dermatol Sci. 2016;84(1):24\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.06.011.","journal-title":"J Dermatol Sci"},{"key":"272_CR155","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2013.11.020","volume":"429","author":"Y Muro","year":"2014","unstructured":"Muro Y, Sugiura K, Shiraki A, Ishii N, Hashimoto T, Akiyama M. Detection of autoantibodies to periplakin and envoplakin in paraneoplastic pemphigus but not idiopathic pulmonary fibrosis using full-length recombinant proteins. Clin Chim Acta. 2014;429:14\u20137. https:\/\/doi.org\/10.1016\/j.cca.2013.11.020.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"272_CR156","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jaad.2024.10.013","volume":"92","author":"Z Min","year":"2024","unstructured":"Min Z, Kun Z, Yue Z, Luyuan L, Jishu L, Jingya G, et al. A systematic review of paraneoplastic pemphigus and paraneoplastic autoimmune multiorgan syndrome: clinical features and prognostic factors. J Am Acad Dermatol. 2024;92(2):307\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.013.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"272_CR157","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12032-009-9304-y","volume":"27","author":"Y Fang","year":"2010","unstructured":"Fang Y, Zhao L, Yan F, Cui X, Xia Y, Duren A. A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman\u2019s disease. Med Oncol. 2010;27(3):907\u201311. https:\/\/doi.org\/10.1007\/s12032-009-9304-y.","journal-title":"Med Oncol"},{"issue":"2","key":"272_CR158","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00432-010-0874-z","volume":"137","author":"J Zhang","year":"2011","unstructured":"Zhang J, Qiao QL, Chen XX, Liu P, Qiu JX, Zhao H, et al. Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases. J Cancer Res Clin Oncol. 2011;137(2):229\u201334. https:\/\/doi.org\/10.1007\/s00432-010-0874-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"272_CR159","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","volume":"10","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa. Front Immunol. 2019;10:1259. https:\/\/doi.org\/10.3389\/fimmu.2019.01259.","journal-title":"Front Immunol"},{"issue":"4","key":"272_CR160","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","volume":"94","author":"CW Maruta","year":"2019","unstructured":"Maruta CW, Miyamoto D, Aoki V, Carvalho RGR, Cunha BM, Santi CG. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview. An Bras Dermatol. 2019;94(4):388\u201398. https:\/\/doi.org\/10.1590\/abd1806-4841.20199165.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"272_CR161","doi-asserted-by":"publisher","first-page":"e14353","DOI":"10.1111\/dth.14353","volume":"33","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang Y, Pan M. Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. Dermatol Ther. 2020;33(6):e14353. https:\/\/doi.org\/10.1111\/dth.14353.","journal-title":"Dermatol Ther"},{"issue":"1","key":"272_CR162","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-3083.2005.01345.x","volume":"20","author":"M Barnadas","year":"2006","unstructured":"Barnadas M, Roe E, Brunet S, Garcia P, Bergua P, Pimentel L, et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol. 2006;20(1):69\u201374. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01345.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"272_CR163","first-page":"269","volume":"137","author":"L Borradori","year":"2001","unstructured":"Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137(3):269\u201372.","journal-title":"Arch Dermatol"},{"issue":"2","key":"272_CR164","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bjd.12324","volume":"169","author":"R Bech","year":"2013","unstructured":"Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d\u2019Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol. 2013;169(2):469\u201372. https:\/\/doi.org\/10.1111\/bjd.12324.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR165","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.det.2011.06.016","volume":"29","author":"JW Frew","year":"2011","unstructured":"Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29(4):607\u201312. https:\/\/doi.org\/10.1016\/j.det.2011.06.016.","journal-title":"Dermatol Clin"},{"key":"272_CR166","doi-asserted-by":"publisher","first-page":"1132535","DOI":"10.3389\/fmed.2023.1132535","volume":"10","author":"C Chen","year":"2023","unstructured":"Chen C, Xu Y, Yu J, Qian S, Xie Y. A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL. Front Med (Lausanne). 2023;10:1132535. https:\/\/doi.org\/10.3389\/fmed.2023.1132535.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"272_CR167","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-4632.2011.04868.x","volume":"50","author":"A Czernik","year":"2011","unstructured":"Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50(8):905\u201314. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.04868.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"272_CR168","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/crj.13465","volume":"16","author":"W Chen","year":"2022","unstructured":"Chen W, Zhao L, Guo L, Zhao L, Niu H, Lian H, et al. Clinical and pathological features of bronchiolitis obliterans requiring lung transplantation in paraneoplastic pemphigus associated with Castleman disease. Clin Respir J. 2022;16(3):173\u201381. https:\/\/doi.org\/10.1111\/crj.13465.","journal-title":"Clin Respir J"},{"issue":"3","key":"272_CR169","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.det.2011.03.018","volume":"29","author":"JW Frew","year":"2011","unstructured":"Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011;29(3):419\u201325, vii. https:\/\/doi.org\/10.1016\/j.det.2011.03.018.","journal-title":"Dermatol Clin."},{"issue":"3","key":"272_CR170","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/scd.12093","volume":"35","author":"G Al Zamel","year":"2015","unstructured":"Al Zamel G, Micheletti RG, Nasta SD, Palakshappa J, Stoopler ET. The importance of multidisciplinary healthcare for paraneoplastic pemphigus. Spec Care Dentist. 2015;35(3):143\u20137. https:\/\/doi.org\/10.1111\/scd.12093.","journal-title":"Spec Care Dentist"},{"issue":"1","key":"272_CR171","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6\u201317. https:\/\/doi.org\/10.1007\/s12026-017-8975-2.","journal-title":"Immunol Res"},{"issue":"5","key":"272_CR172","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia. Germany J Dtsch Dermatol Ges. 2009;7(5):434\u201340. https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06976.x.","journal-title":"Germany J Dtsch Dermatol Ges"},{"issue":"3","key":"272_CR173","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/1523-1747.ep12343631","volume":"106","author":"D Zillikens","year":"1996","unstructured":"Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol. 1996;106(3):465\u201370. https:\/\/doi.org\/10.1111\/1523-1747.ep12343631.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"272_CR174","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1365-2133.1996.tb07625.x","volume":"134","author":"KR Chen","year":"1996","unstructured":"Chen KR, Shimizu S, Miyakawa S, Ishiko A, Shimizu H, Hashimoto T. Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis: identification of a novel 200-kDa lower lamina lucida target antigen. Br J Dermatol. 1996;134(2):340\u20136.","journal-title":"Br J Dermatol"},{"issue":"16","key":"272_CR175","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1073\/pnas.93.16.8569","volume":"93","author":"JC Delgado","year":"1996","unstructured":"Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A. 1996;93(16):8569\u201371. https:\/\/doi.org\/10.1073\/pnas.93.16.8569.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"272_CR176","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1346-8138.2000.tb02141.x","volume":"27","author":"A Okazaki","year":"2000","unstructured":"Okazaki A, Miyagawa S, Yamashina Y, Kitamura W, Shirai T. Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol. 2000;27(3):149\u201356. https:\/\/doi.org\/10.1111\/j.1346-8138.2000.tb02141.x.","journal-title":"J Dermatol"},{"issue":"1","key":"272_CR177","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.autrev.2011.07.002","volume":"11","author":"LR Zakka","year":"2011","unstructured":"Zakka LR, Reche P, Ahmed AR. Role of MHC Class II genes in the pathogenesis of pemphigoid. Autoimmun Rev. 2011;11(1):40\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2011.07.002.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"272_CR178","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/1523-1747.ep12470317","volume":"91","author":"WR Gammon","year":"1988","unstructured":"Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, Briggaman RA. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988;91(3):228\u201332. https:\/\/doi.org\/10.1111\/1523-1747.ep12470317.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"272_CR179","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/jid.2011.231","volume":"131","author":"C Zumelzu","year":"2011","unstructured":"Zumelzu C, Le Roux-Villet C, Loiseau P, Busson M, Heller M, Aucouturier F, et al. Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol. 2011;131(12):2386\u201393. https:\/\/doi.org\/10.1038\/jid.2011.231.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"272_CR180","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000246282","volume":"193","author":"CW Lee","year":"1996","unstructured":"Lee CW, Kim SC, Han H. Distribution of HLA class II alleles in Korean patients with epidermolysis bullosa acquisita. Dermatology. 1996;193(4):328\u20139. https:\/\/doi.org\/10.1159\/000246282.","journal-title":"Dermatology"},{"issue":"10","key":"272_CR181","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","volume":"10","author":"F Moro","year":"2020","unstructured":"Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10(10):1432. https:\/\/doi.org\/10.3390\/biom10101432.","journal-title":"Biomolecules."},{"issue":"12","key":"272_CR182","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI3335","volume":"102","author":"L Budinger","year":"1998","unstructured":"Budinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998;102(12):2082\u20139. https:\/\/doi.org\/10.1172\/JCI3335.","journal-title":"J Clin Invest"},{"issue":"9","key":"272_CR183","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jid.2018.03.1515","volume":"138","author":"J Zhang","year":"2018","unstructured":"Zhang J, Fang H, Shen S, Dang E, Li Q, Qiao P, et al. Identification of immunodominant Th2-cell epitopes in Chinese patients with bullous pemphigoid. J Invest Dermatol. 2018;138(9):1917\u201324. https:\/\/doi.org\/10.1016\/j.jid.2018.03.1515.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"272_CR184","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1172\/JCI17891","volume":"116","author":"KC Nelson","year":"2006","unstructured":"Nelson KC, Zhao M, Schroeder PR, Li N, Wetsel RA, Diaz LA, et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest. 2006;116(11):2892\u2013900. https:\/\/doi.org\/10.1172\/JCI17891.","journal-title":"J Clin Invest"},{"issue":"5","key":"272_CR185","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92(5):2480\u20138. https:\/\/doi.org\/10.1172\/JCI116856.","journal-title":"J Clin Invest"},{"issue":"4","key":"272_CR186","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","volume":"95","author":"Z Liu","year":"1995","unstructured":"Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest. 1995;95(4):1539\u201344. https:\/\/doi.org\/10.1172\/JCI117826.","journal-title":"J Clin Invest"},{"issue":"1","key":"272_CR187","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","volume":"105","author":"Z Liu","year":"2000","unstructured":"Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105(1):113\u201323. https:\/\/doi.org\/10.1172\/JCI3693.","journal-title":"J Clin Invest"},{"issue":"8","key":"272_CR188","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","volume":"108","author":"R Chen","year":"2001","unstructured":"Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, Werb Z, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108(8):1151\u20138. https:\/\/doi.org\/10.1172\/JCI11494.","journal-title":"J Clin Invest"},{"issue":"5","key":"272_CR189","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/s0092-8674(00)00087-8","volume":"102","author":"Z Liu","year":"2000","unstructured":"Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B\/MMP-9 in vivo. Cell. 2000;102(5):647\u201355. https:\/\/doi.org\/10.1016\/s0092-8674(00)00087-8.","journal-title":"Cell"},{"issue":"11","key":"272_CR190","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","volume":"127","author":"JA Fairley","year":"2007","unstructured":"Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice. J Invest Dermatol. 2007;127(11):2605\u201311. https:\/\/doi.org\/10.1038\/sj.jid.5700958.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"272_CR191","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","volume":"127","author":"JJ Zone","year":"2007","unstructured":"Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol. 2007;127(5):1167\u201374. https:\/\/doi.org\/10.1038\/sj.jid.5700681.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"272_CR192","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","volume":"129","author":"H Iwata","year":"2009","unstructured":"Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol. 2009;129(4):919\u201326. https:\/\/doi.org\/10.1038\/jid.2008.305.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"272_CR193","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","volume":"182","author":"S Hiroyasu","year":"2013","unstructured":"Hiroyasu S, Ozawa T, Kobayashi H, Ishii M, Aoyama Y, Kitajima Y, et al. Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway. Am J Pathol. 2013;182(3):828\u201340. https:\/\/doi.org\/10.1016\/j.ajpath.2012.11.029.","journal-title":"Am J Pathol"},{"key":"272_CR194","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM, Kunstner A, Goletz S, Petersen BS, Thaci D, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2018.09.003.","journal-title":"J Autoimmun"},{"issue":"2","key":"272_CR195","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","volume":"180","author":"WJ Pickford","year":"2015","unstructured":"Pickford WJ, Gudi V, Haggart AM, Lewis BJ, Herriot R, Barker RN, et al. T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid. Clin Exp Immunol. 2015;180(2):189\u2013200. https:\/\/doi.org\/10.1111\/cei.12566.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"272_CR196","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","volume":"134","author":"S Le Jan","year":"2014","unstructured":"Le Jan S, Plee J, Vallerand D, Dupont A, Delanez E, Durlach A, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol. 2014;134(12):2908\u201317. https:\/\/doi.org\/10.1038\/jid.2014.263.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"272_CR197","doi-asserted-by":"publisher","first-page":"e68145","DOI":"10.1371\/journal.pone.0068145","volume":"8","author":"Q Li","year":"2013","unstructured":"Li Q, Liu Z, Dang E, Jin L, He Z, Yang L, et al. Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid. PLoS ONE. 2013;8(7):e68145. https:\/\/doi.org\/10.1371\/journal.pone.0068145.","journal-title":"PLoS ONE"},{"issue":"8","key":"272_CR198","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1073\/pnas.0809230106","volume":"106","author":"T Dainichi","year":"2009","unstructured":"Dainichi T, Kurono S, Ohyama B, Ishii N, Sanzen N, Hayashi M, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A. 2009;106(8):2800\u20135. https:\/\/doi.org\/10.1073\/pnas.0809230106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2 Pt 1","key":"272_CR199","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0190-9622(85)70163-6","volume":"13","author":"MH Grunwald","year":"1985","unstructured":"Grunwald MH, David M, Feuerman EJ. Coexistence of psoriasis vulgaris and bullous diseases. J Am Acad Dermatol. 1985;13(2 Pt 1):224\u20138. https:\/\/doi.org\/10.1016\/s0190-9622(85)70163-6.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"272_CR200","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1346-8138.2009.00793.x","volume":"37","author":"T Dainichi","year":"2010","unstructured":"Dainichi T, Koga H, Tsuji T, Ishii N, Ohyama B, Ueda A, et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol. 2010;37(3):231\u20138. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00793.x.","journal-title":"J Dermatol"},{"issue":"4","key":"272_CR201","doi-asserted-by":"publisher","first-page":"103036","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev. 2022;21(4):103036. https:\/\/doi.org\/10.1016\/j.autrev.2022.103036.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"272_CR202","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/jid.2010.248","volume":"131","author":"RJ Ludwig","year":"2011","unstructured":"Ludwig RJ, Recke A, Bieber K, Muller S, Marques Ade C, Banczyk D, et al. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol. 2011;131(1):167\u201376. https:\/\/doi.org\/10.1038\/jid.2010.248.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR203","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s0002-9440(10)64182-x","volume":"161","author":"C Sitaru","year":"2002","unstructured":"Sitaru C, Kromminga A, Hashimoto T, Brocker EB, Zillikens D. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol. 2002;161(1):301\u201311. https:\/\/doi.org\/10.1016\/s0002-9440(10)64182-x.","journal-title":"Am J Pathol"},{"issue":"5","key":"272_CR204","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/path.1674","volume":"204","author":"I Shimanovich","year":"2004","unstructured":"Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Brocker EB, Opdenakker G, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol. 2004;204(5):519\u201327. https:\/\/doi.org\/10.1002\/path.1674.","journal-title":"J Pathol"},{"issue":"23","key":"272_CR205","doi-asserted-by":"publisher","first-page":"13739","DOI":"10.1074\/jbc.271.23.13739","volume":"271","author":"Y Hirako","year":"1996","unstructured":"Hirako Y, Usukura J, Nishizawa Y, Owaribe K. Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. J Biol Chem. 1996;271(23):13739\u201345. https:\/\/doi.org\/10.1074\/jbc.271.23.13739.","journal-title":"J Biol Chem"},{"issue":"12","key":"272_CR206","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.13446","volume":"26","author":"S Goletz","year":"2017","unstructured":"Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol. 2017;26(12):1154\u201362. https:\/\/doi.org\/10.1111\/exd.13446.","journal-title":"Exp Dermatol"},{"issue":"12","key":"272_CR207","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.1016\/S0021-9258(18)52948-3","volume":"268","author":"K Li","year":"1993","unstructured":"Li K, Tamai K, Tan EM, Uitto J. Cloning of type XVII collagen. Complementary and genomic DNA sequences of mouse 180-kilodalton bullous pemphigoid antigen (BPAG2) predict an interrupted collagenous domain, a transmembrane segment, and unusual features in the 5\u2019-end of the gene and the 3\u2019-untranslated region of the mRNA. J Biol Chem. 1993;268(12):8825\u201334.","journal-title":"J Biol Chem."},{"issue":"4","key":"272_CR208","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s004030050392","volume":"291","author":"D Zillikens","year":"1999","unstructured":"Zillikens D, Giudice GJ. BP180\/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. Arch Dermatol Res. 1999;291(4):187\u201394. https:\/\/doi.org\/10.1007\/s004030050392.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"272_CR209","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1016\/0923-1811(93)90940-q","volume":"151","author":"GJ Giudice","year":"1993","unstructured":"Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151(10):5742\u201350. https:\/\/doi.org\/10.1016\/0923-1811(93)90940-q.","journal-title":"J Immunol"},{"issue":"4","key":"272_CR210","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","volume":"109","author":"D Zillikens","year":"1997","unstructured":"Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol. 1997;109(4):573\u20139. https:\/\/doi.org\/10.1111\/1523-1747.ep12337492.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"272_CR211","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1600-0625.2010.01080.x","volume":"19","author":"B Horvath","year":"2010","unstructured":"Horvath B, Niedermeier A, Podstawa E, Muller R, Hunzelmann N, Karpati S, et al. IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis. Exp Dermatol. 2010;19(7):648\u201353. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01080.x.","journal-title":"Exp Dermatol"},{"issue":"4","key":"272_CR212","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1067\/mjd.2000.103986","volume":"42","author":"R Dopp","year":"2000","unstructured":"Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000;42(4):577\u201383. https:\/\/doi.org\/10.1067\/mjd.2000.103986.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"272_CR213","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1684\/ejd.2023.4573","volume":"33","author":"C Sun","year":"2023","unstructured":"Sun C, Qian H, Liang G, Xiang R, Zhao C, Li Z, et al. IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid. Eur J Dermatol. 2023;33(6):595\u2013603. https:\/\/doi.org\/10.1684\/ejd.2023.4573.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"272_CR214","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","volume":"87","author":"A Salemme","year":"2022","unstructured":"Salemme A, Fania L, Scarabello A, Caproni M, Marzano AV, Cozzani E, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol. 2022;87(1):56\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.036.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"272_CR215","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.0022-202X.2003.22126.x","volume":"122","author":"G Di Zenzo","year":"2004","unstructured":"Di Zenzo G, Grosso F, Terracina M, Mariotti F, De Pita O, Owaribe K, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol. 2004;122(1):103\u201310. https:\/\/doi.org\/10.1046\/j.0022-202X.2003.22126.x.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"272_CR216","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/1523-1747.ep12382738","volume":"102","author":"GJ Giudice","year":"1994","unstructured":"Giudice GJ, Wilske KC, Anhalt GJ, Fairley JA, Taylor AF, Emery DJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 1994;102(6):878\u201381. https:\/\/doi.org\/10.1111\/1523-1747.ep12382738.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR217","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0923-1811(97)00067-4","volume":"17","author":"H Murakami","year":"1998","unstructured":"Murakami H, Nishioka S, Setterfield J, Bhogal BS, Black MM, Zillikens D, et al. Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. J Dermatol Sci. 1998;17(1):39\u201344. https:\/\/doi.org\/10.1016\/s0923-1811(97)00067-4.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"272_CR218","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1523-1747.1999.00497.x","volume":"112","author":"J Perriard","year":"1999","unstructured":"Perriard J, Jaunin F, Favre B, Budinger L, Hertl M, Saurat JH, et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol. 1999;112(2):141\u20137. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00497.x.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"272_CR219","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1365-2133.2001.04130.x","volume":"144","author":"E Laffitte","year":"2001","unstructured":"Laffitte E, Skaria M, Jaunin F, Tamm K, Saurat JH, Favre B, et al. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol. 2001;144(4):760\u20138. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04130.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"272_CR220","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1172\/JCI113803","volume":"82","author":"JR Stanley","year":"1988","unstructured":"Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients\u2019 autoantibodies. J Clin Invest. 1988;82(6):1864\u201370. https:\/\/doi.org\/10.1172\/JCI113803.","journal-title":"J Clin Invest"},{"issue":"5","key":"272_CR221","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1046\/j.1523-1747.1999.00576.x","volume":"112","author":"A Sonnenberg","year":"1999","unstructured":"Sonnenberg A, Nievers M, Schaapveld R, Geerts D, Niessen C, Borradori L. Interaction of BP180 and alpha6beta4. J Invest Dermatol. 1999;112(5):830\u20132. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00576.x.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR222","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1091\/mbc.11.1.277","volume":"11","author":"SB Hopkinson","year":"2000","unstructured":"Hopkinson SB, Jones JCR. The N terminus of the transmembrane protein BP180 interacts with the N-terminal domain of BP230, thereby mediating keratin cytoskeleton anchorage to the cell surface at the site of the hemidesmosome. Mol Biol Cell. 2000;11(1):277\u201386. https:\/\/doi.org\/10.1091\/mbc.11.1.277.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"272_CR223","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjd.12479","volume":"169","author":"AM Poot","year":"2013","unstructured":"Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2013;169(5):1016\u201324. https:\/\/doi.org\/10.1111\/bjd.12479.","journal-title":"Br J Dermatol"},{"issue":"1","key":"272_CR224","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1523-1747.ep13070476","volume":"92","author":"S Mueller","year":"1989","unstructured":"Mueller S, Klaus-Kovtun V, Stanley JR. A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol. 1989;92(1):33\u20138. https:\/\/doi.org\/10.1111\/1523-1747.ep13070476.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"272_CR225","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1523-1747.ep12371694","volume":"101","author":"JE Miller","year":"1993","unstructured":"Miller JE, Rico MJ, Hall RP 3rd. IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol. 1993;101(6):779\u201382. https:\/\/doi.org\/10.1111\/1523-1747.ep12371694.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"272_CR226","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/0923-1811(95)00479-3","volume":"12","author":"MJ Rico","year":"1996","unstructured":"Rico MJ, Hashimototo T, Watanabe K, Hall RP, Clark RB, Nishikawa T. Comparative epitope mapping of sera from United States (US) and Japanese patients with bullous pemphigoid (BP) to fusion proteins encoded by BPAG1. J Dermatol Sci. 1996;12(3):238\u201345. https:\/\/doi.org\/10.1016\/0923-1811(95)00479-3.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"272_CR227","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2133.1995.tb05012.x","volume":"132","author":"M Gaucherand","year":"1995","unstructured":"Gaucherand M, Nicolas JF, Paranhos Baccala G, Rouault JP, Reano A, Magaud JP, et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein. Evidence using a 55 kDa recombinant protein. Br J Dermatol. 1995;132(2):190\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb05012.x.","journal-title":"Br J Dermatol."},{"issue":"3","key":"272_CR228","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1023\/a:1020531005776","volume":"18","author":"RF Ghohestani","year":"1998","unstructured":"Ghohestani RF, Cozzani E, Delaporte E, Nicolas JF, Parodi A, Claudy A. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol. 1998;18(3):202\u20139. https:\/\/doi.org\/10.1023\/a:1020531005776.","journal-title":"J Clin Immunol"},{"issue":"4","key":"272_CR229","first-page":"193","volume":"53","author":"E Peyron","year":"1995","unstructured":"Peyron E, Bour H, Gaucherand M, Nicolas JF. Study of epitopic sites of the major bullous pemphigoid antigen (BPAg1). Ann Biol Clin (Paris). 1995;53(4):193\u20137 (Etude des sites epitopiques de l&apos;antigene majeur de la pemphigoide bulleuse (BPAg1)).","journal-title":"Ann Biol Clin (Paris)."},{"issue":"3","key":"272_CR230","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","volume":"128","author":"G Di Zenzo","year":"2008","unstructured":"Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008;128(3):415\u201326. https:\/\/doi.org\/10.1016\/j.clim.2008.04.012.","journal-title":"Clin Immunol"},{"issue":"5","key":"272_CR231","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1046\/j.1523-1747.2000.00893.x","volume":"114","author":"M Skaria","year":"2000","unstructured":"Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tuderman L, et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol. 2000;114(5):998\u20131004. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00893.x.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"272_CR232","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","volume":"166","author":"IM Blocker","year":"2012","unstructured":"Blocker IM, Dahnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, et al. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol. 2012;166(5):964\u201370. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10820.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"272_CR233","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0923-1811(99)00093-6","volume":"23","author":"Y Kawahara","year":"2000","unstructured":"Kawahara Y, Zillikens D, Yancey KB, Marinkovich MP, Nie Z, Hashimoto T, et al. Subepidermal blistering disease with autoantibodies against a novel dermal 200-kDa antigen. J Dermatol Sci. 2000;23(2):93\u2013102. https:\/\/doi.org\/10.1016\/s0923-1811(99)00093-6.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"272_CR234","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2133.2010.10056.x","volume":"164","author":"S Groth","year":"2011","unstructured":"Groth S, Recke A, Vafia K, Ludwig RJ, Hashimoto T, Zillikens D, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol. 2011;164(1):76\u201382. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10056.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"272_CR235","doi-asserted-by":"publisher","first-page":"e41769","DOI":"10.1371\/journal.pone.0041769","volume":"7","author":"K Vafia","year":"2012","unstructured":"Vafia K, Groth S, Beckmann T, Hirose M, Dworschak J, Recke A, et al. Pathogenicity of autoantibodies in anti-p200 pemphigoid. PLoS ONE. 2012;7(7):e41769. https:\/\/doi.org\/10.1371\/journal.pone.0041769.","journal-title":"PLoS ONE"},{"issue":"2","key":"272_CR236","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ajpath.2013.10.019","volume":"184","author":"F Florea","year":"2014","unstructured":"Florea F, Bernards C, Caproni M, Kleindienst J, Hashimoto T, Koch M, et al. Ex vivo pathogenicity of anti-laminin gamma1 autoantibodies. Am J Pathol. 2014;184(2):494\u2013506. https:\/\/doi.org\/10.1016\/j.ajpath.2013.10.019.","journal-title":"Am J Pathol"},{"issue":"2","key":"272_CR237","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jdermsci.2014.12.003","volume":"77","author":"X Li","year":"2015","unstructured":"Li X, Qian H, Takizawa M, Koga H, Tsuchisaka A, Ishii N, et al. N-linked glycosylation on laminin gamma1 influences recognition of anti-laminin gamma1 pemphigoid autoantibodies. J Dermatol Sci. 2015;77(2):125\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.12.003.","journal-title":"J Dermatol Sci"},{"issue":"25","key":"272_CR238","doi-asserted-by":"publisher","first-page":"17900","DOI":"10.1016\/s0021-9258(19)37127-3","volume":"267","author":"MP Marinkovich","year":"1992","unstructured":"Marinkovich MP, Lunstrum GP, Burgeson RE. The anchoring filament protein kalinin is synthesized and secreted as a high-molecular-weight precursor. J Biol Chem. 1992;267(25):17900\u20136. https:\/\/doi.org\/10.1016\/s0021-9258(19)37127-3.","journal-title":"J Biol Chem"},{"issue":"6","key":"272_CR239","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1083\/jcb.132.6.1189","volume":"132","author":"MF Champliaud","year":"1996","unstructured":"Champliaud MF, Lunstrum GP, Rousselle P, Nishiyama T, Keene DR, Burgeson RE. Human amnion contains a novel laminin variant, laminin 7, which like laminin 6, covalently associates with laminin 5 to promote stable epithelial-stromal attachment. J Cell Biol. 1996;132(6):1189\u201398. https:\/\/doi.org\/10.1083\/jcb.132.6.1189.","journal-title":"J Cell Biol"},{"issue":"30","key":"272_CR240","doi-asserted-by":"publisher","first-page":"22728","DOI":"10.1074\/jbc.M002345200","volume":"275","author":"S Amano","year":"2000","unstructured":"Amano S, Scott IC, Takahara K, Koch M, Champliaud MF, Gerecke DR, et al. Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 gamma 2 chain. J Biol Chem. 2000;275(30):22728\u201335. https:\/\/doi.org\/10.1074\/jbc.M002345200.","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"272_CR241","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0022-1759(99)00019-8","volume":"224","author":"S Amano","year":"1999","unstructured":"Amano S, Nishiyama T, Burgeson RE. A specific and sensitive ELISA for laminin 5. J Immunol Methods. 1999;224(1\u20132):161\u20139. https:\/\/doi.org\/10.1016\/s0022-1759(99)00019-8.","journal-title":"J Immunol Methods"},{"issue":"Suppl 1(0)","key":"272_CR242","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/s0923-1811(00)00142-0","volume":"24","author":"T Nishiyama","year":"2000","unstructured":"Nishiyama T, Amano S, Tsunenaga M, Kadoya K, Takeda A, Adachi E, et al. The importance of laminin 5 in the dermal-epidermal basement membrane. J Dermatol Sci. 2000;24(Suppl 1(0)):S51\u20139. https:\/\/doi.org\/10.1016\/s0923-1811(00)00142-0.","journal-title":"J Dermatol Sci."},{"issue":"6","key":"272_CR243","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/1523-1747.ep12292578","volume":"108","author":"LS Chan","year":"1997","unstructured":"Chan LS, Majmudar AA, Tran HH, Meier F, Schaumburg-Lever G, Chen M, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol. 1997;108(6):848\u201353. https:\/\/doi.org\/10.1111\/1523-1747.ep12292578.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"272_CR244","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1046\/j.1365-2133.1998.02502.x","volume":"139","author":"Z Lazarova","year":"1998","unstructured":"Lazarova Z, Hsu R, Yee C, Yancey KB. Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). Br J Dermatol. 1998;139(5):791\u20137. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02502.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR245","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/1523-1747.ep12323431","volume":"105","author":"G Kirtschig","year":"1995","unstructured":"Kirtschig G, Marinkovich MP, Burgeson RE, Yancey KB. Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol. 1995;105(4):543\u20138. https:\/\/doi.org\/10.1111\/1523-1747.ep12323431.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"272_CR246","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/clim.2001.5091","volume":"101","author":"Z Lazarova","year":"2001","unstructured":"Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol. 2001;101(1):100\u20135. https:\/\/doi.org\/10.1006\/clim.2001.5091.","journal-title":"Clin Immunol"},{"issue":"2","key":"272_CR247","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0923-1811(03)00158-0","volume":"33","author":"Y Hisamatsu","year":"2003","unstructured":"Hisamatsu Y, Nishiyama T, Amano S, Matsui C, Ghohestani R, Hashimoto T. Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci. 2003;33(2):113\u20139. https:\/\/doi.org\/10.1016\/s0923-1811(03)00158-0.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"272_CR248","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/archderm.135.2.173","volume":"135","author":"HC Nousari","year":"1999","unstructured":"Nousari HC, Rencic A, Hsu R, Yancey KB, Anhalt GJ. Anti-epiligrin cicatricial pemphigoid with antibodies against the gamma2 subunit of laminin 5. Arch Dermatol. 1999;135(2):173\u20136. https:\/\/doi.org\/10.1001\/archderm.135.2.173.","journal-title":"Arch Dermatol"},{"issue":"5","key":"272_CR249","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","volume":"149","author":"P Bernard","year":"2013","unstructured":"Bernard P, Antonicelli F, Bedane C, Joly P, Le Roux-Villet C, Duvert-Lehembre S, et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol. 2013;149(5):533\u201340. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1434.","journal-title":"JAMA Dermatol"},{"issue":"25","key":"272_CR250","doi-asserted-by":"publisher","first-page":"14714","DOI":"10.1073\/pnas.93.25.14714","volume":"93","author":"S Tyagi","year":"1996","unstructured":"Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A. 1996;93(25):14714\u20139. https:\/\/doi.org\/10.1073\/pnas.93.25.14714.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"272_CR251","first-page":"379","volume":"42","author":"S Kumari","year":"2001","unstructured":"Kumari S, Bhol KC, Simmons RK, Razzaque MS, Letko E, Foster CS, et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest Ophthalmol Vis Sci. 2001;42(2):379\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"272_CR252","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/jimmunol.176.3.1968","volume":"176","author":"KA Rashid","year":"2006","unstructured":"Rashid KA, Stern JN, Ahmed AR. Identification of an epitope within human integrin alpha 6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid. J Immunol. 2006;176(3):1968\u201377. https:\/\/doi.org\/10.4049\/jimmunol.176.3.1968.","journal-title":"J Immunol"},{"issue":"12","key":"272_CR253","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1167\/iovs.12-11404","volume":"54","author":"KA Rashid","year":"2013","unstructured":"Rashid KA, Foster CS, Ahmed AR. Identification of epitopes within integrin beta4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report. Invest Ophthalmol Vis Sci. 2013;54(12):7707\u201316. https:\/\/doi.org\/10.1167\/iovs.12-11404.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"272_CR254","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1523-1747.ep12365129","volume":"101","author":"RE Burgeson","year":"1993","unstructured":"Burgeson RE. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol. 1993;101(3):252\u20135. https:\/\/doi.org\/10.1111\/1523-1747.ep12365129.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"272_CR255","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1083\/jcb.104.3.611","volume":"104","author":"DR Keene","year":"1987","unstructured":"Keene DR, Sakai LY, Lunstrum GP, Morris NP, Burgeson RE. Type VII collagen forms an extended network of anchoring fibrils. J Cell Biol. 1987;104(3):611\u201321. https:\/\/doi.org\/10.1083\/jcb.104.3.611.","journal-title":"J Cell Biol"},{"issue":"4","key":"272_CR256","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1083\/jcb.103.4.1577","volume":"103","author":"LY Sakai","year":"1986","unstructured":"Sakai LY, Keene DR, Morris NP, Burgeson RE. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol. 1986;103(4):1577\u201386. https:\/\/doi.org\/10.1083\/jcb.103.4.1577.","journal-title":"J Cell Biol"},{"issue":"16","key":"272_CR257","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJM198404193101602","volume":"310","author":"DT Woodley","year":"1984","unstructured":"Woodley DT, Briggaman RA, O\u2019Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984;310(16):1007\u201313. https:\/\/doi.org\/10.1056\/NEJM198404193101602.","journal-title":"N Engl J Med"},{"issue":"4","key":"272_CR258","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1172\/JCI116774","volume":"92","author":"JC Lapiere","year":"1993","unstructured":"Lapiere JC, Woodley DT, Parente MG, Iwasaki T, Wynn KC, Christiano AM, et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest. 1993;92(4):1831\u20139. https:\/\/doi.org\/10.1172\/JCI116774.","journal-title":"J Clin Invest."},{"issue":"5","key":"272_CR259","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/1523-1747.ep12374333","volume":"102","author":"T Tanaka","year":"1994","unstructured":"Tanaka T, Furukawa F, Imamura S. Epitope mapping for epidermolysis bullosa acquisita autoantibody by molecularly cloned cDNA for type VII collagen. J Invest Dermatol. 1994;102(5):706\u20139. https:\/\/doi.org\/10.1111\/1523-1747.ep12374333.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"272_CR260","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2353\/ajpath.2007.061212","volume":"170","author":"M Chen","year":"2007","unstructured":"Chen M, Doostan A, Bandyopadhyay P, Remington J, Wang X, Hou Y, et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol. 2007;170(6):2009\u201318. https:\/\/doi.org\/10.2353\/ajpath.2007.061212.","journal-title":"Am J Pathol"},{"issue":"5","key":"272_CR261","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/1523-1747.ep12472291","volume":"100","author":"WR Gammon","year":"1993","unstructured":"Gammon WR, Murrell DF, Jenison MW, Padilla KM, Prisayanh PS, Jones DA, et al. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol. 1993;100(5):618\u201322. https:\/\/doi.org\/10.1111\/1523-1747.ep12472291.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"272_CR262","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1365-2133.2004.05933.x","volume":"150","author":"N Ishii","year":"2004","unstructured":"Ishii N, Yoshida M, Hisamatsu Y, Ishida-Yamamoto A, Nakane H, Iizuka H, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol. 2004;150(5):843\u201351. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05933.x.","journal-title":"Br J Dermatol"},{"issue":"24","key":"272_CR263","doi-asserted-by":"publisher","first-page":"21649","DOI":"10.1074\/jbc.M100180200","volume":"276","author":"M Chen","year":"2001","unstructured":"Chen M, Keene DR, Costa FK, Tahk SH, Woodley DT. The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies. J Biol Chem. 2001;276(24):21649\u201355. https:\/\/doi.org\/10.1074\/jbc.M100180200.","journal-title":"J Biol Chem"},{"issue":"3","key":"272_CR264","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jdermsci.2011.03.003","volume":"62","author":"MA Saleh","year":"2011","unstructured":"Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, et al. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci. 2011;62(3):169\u201375. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.03.003.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"272_CR265","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689\u2013704. https:\/\/doi.org\/10.1111\/jdv.18220.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"272_CR266","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1346-8138.15111","volume":"46","author":"H Ujiie","year":"2019","unstructured":"Ujiie H, Iwata H, Yamagami J, Nakama T, Aoyama Y, Ikeda S, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019;46(12):1102\u201335. https:\/\/doi.org\/10.1111\/1346-8138.15111.","journal-title":"J Dermatol"},{"key":"272_CR267","doi-asserted-by":"publisher","unstructured":"Dermatology CSo, Association CD, Gang W, Hongzhong J. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases. Chin J Dermatol. 2022;2022:55.\u00a0https:\/\/doi.org\/10.35541\/cjd.20210532.","DOI":"10.35541\/cjd.20210532"},{"issue":"7","key":"272_CR268","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/ddg.12564","volume":"13","author":"A Gawaz","year":"2015","unstructured":"Gawaz A, Metzler G, Hertl M, Hashimoto T, Schaller M. Treatment of anti-laminin gamma1 pemphigoid with mycophenolate mofetil. J Dtsch Dermatol Ges. 2015;13(7):696\u20137. https:\/\/doi.org\/10.1111\/ddg.12564.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"272_CR269","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1111\/1346-8138.16864","volume":"50","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zhou Y, Qian H, Wu F, Liu H, Li X, et al. Anti-laminin gamma1 (p200) pemphigoid successfully treated with tofacitinib combined with prednisone. J Dermatol. 2023;50(10):e354\u20136. https:\/\/doi.org\/10.1111\/1346-8138.16864.","journal-title":"J Dermatol"},{"issue":"4","key":"272_CR270","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/ijd.15656","volume":"61","author":"ZT Chai","year":"2022","unstructured":"Chai ZT, Lim YL, Busmanis I, Pang SM. Anti-laminin-gamma1 pemphigoid in an epitope spreading phenomenon, successfully treated with rituximab. Int J Dermatol. 2022;61(4):508\u201310. https:\/\/doi.org\/10.1111\/ijd.15656.","journal-title":"Int J Dermatol"},{"issue":"4","key":"272_CR271","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/1346-8138.12798","volume":"42","author":"A Imanishi","year":"2015","unstructured":"Imanishi A, Tateishi C, Imanishi H, Sowa-Osako J, Koga H, Tsuruta D, et al. Pemphigoid with antibodies to laminin gamma1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin. J Dermatol. 2015;42(4):394\u20137. https:\/\/doi.org\/10.1111\/1346-8138.12798.","journal-title":"J Dermatol"},{"issue":"11","key":"272_CR272","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/ddg.14905","volume":"20","author":"SC Hofmann","year":"2022","unstructured":"Hofmann SC, Gunther C, Bockle BC, Didona D, Ehrchen J, Gaskins M, et al. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J Dtsch Dermatol Ges. 2022;20(11):1530\u201350. https:\/\/doi.org\/10.1111\/ddg.14905.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"272_CR273","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","volume":"133","author":"RP Hall 3rd","year":"2013","unstructured":"Hall RP 3rd, Streilein RD, Hannah DL, McNair PD, Fairley JA, Ronaghy A, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786\u20138. https:\/\/doi.org\/10.1038\/jid.2013.236.","journal-title":"J Invest Dermatol"},{"key":"272_CR274","doi-asserted-by":"publisher","first-page":"553075","DOI":"10.3389\/fmed.2020.553075","volume":"7","author":"L Petricca","year":"2020","unstructured":"Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, et al. Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies. Front Med (Lausanne). 2020;7:553075. https:\/\/doi.org\/10.3389\/fmed.2020.553075.","journal-title":"Front Med (Lausanne)"},{"issue":"Pt A","key":"272_CR275","doi-asserted-by":"publisher","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","volume":"125","author":"D Huang","year":"2023","unstructured":"Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol. 2023;125(Pt A):111157. https:\/\/doi.org\/10.1016\/j.intimp.2023.111157.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"272_CR276","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953\u201360. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"272_CR277","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","volume":"123","author":"JA Fairley","year":"2009","unstructured":"Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2008.11.035.","journal-title":"J Allergy Clin Immunol"},{"key":"272_CR278","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","volume":"32","author":"S Youssef","year":"2023","unstructured":"Youssef S, Gallitano S, Bordone LA. Two cases of bullous pemphigoid effectively treated with oral tofacitinib. JAAD Case Rep. 2023;32:77\u201380. https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.028.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"272_CR279","doi-asserted-by":"publisher","first-page":"e15754","DOI":"10.1111\/dth.15754","volume":"35","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther. 2022;35(10):e15754. https:\/\/doi.org\/10.1111\/dth.15754.","journal-title":"Dermatol Ther"},{"key":"272_CR280","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.ajoc.2021.101104","volume":"22","author":"H James","year":"2021","unstructured":"James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22:101104. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101104.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"272_CR281","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaad.2020.12.056","volume":"87","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Rahat S, Mufti A, Witol A, Bagit A, Sachdeva M, et al. Biologic treatment outcomes in mucous membrane pemphigoid: a systematic review. J Am Acad Dermatol. 2022;87(1):110\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.056.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"272_CR282","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/path.6220","volume":"262","author":"M Pigors","year":"2024","unstructured":"Pigors M, Patzelt S, Reichhelm N, Dworschak J, Khil\u2019chenko S, Emtenani S, et al. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade. J Pathol. 2024;262(2):161\u201374. https:\/\/doi.org\/10.1002\/path.6220.","journal-title":"J Pathol"},{"issue":"3","key":"272_CR283","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-023-08973-1","volume":"65","author":"HC Chen","year":"2023","unstructured":"Chen HC, Wang CW, Toh WH, Lee HE, Chung WH, Chen CB. Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches. Clin Rev Allergy Immunol. 2023;65(3):331\u201353. https:\/\/doi.org\/10.1007\/s12016-023-08973-1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"272_CR284","unstructured":"Aslanova M, Yarrarapu SNS, Syed HA, Zito PM. IgA Pemphigus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519063. Accessed 28 Apr 2025."},{"issue":"8","key":"272_CR285","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/medicina57080843","volume":"57","author":"CN Nguyen","year":"2021","unstructured":"Nguyen CN, Kim SJ. Dermatitis herpetiformis: an update on diagnosis, disease monitoring, and management. Medicina (Kaunas). 2021;57(8):843. https:\/\/doi.org\/10.3390\/medicina57080843.","journal-title":"Medicina (Kaunas)."},{"issue":"1","key":"272_CR286","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/003655202753387356","volume":"37","author":"K Hervonen","year":"2002","unstructured":"Hervonen K, Hakanen M, Kaukinen K, Collin P, Reunala T. First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis. Scand J Gastroenterol. 2002;37(1):51\u20135. https:\/\/doi.org\/10.1080\/003655202753387356.","journal-title":"Scand J Gastroenterol"},{"key":"272_CR287","doi-asserted-by":"publisher","first-page":"239691","DOI":"10.1155\/2012\/239691","volume":"2012","author":"D Bonciani","year":"2012","unstructured":"Bonciani D, Verdelli A, Bonciolini V, D\u2019Errico A, Antiga E, Fabbri P, et al. Dermatitis herpetiformis: from the genetics to the development of skin lesions. Clin Dev Immunol. 2012;2012:239691. https:\/\/doi.org\/10.1155\/2012\/239691.","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"272_CR288","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0923-1811(95)00449-1","volume":"12","author":"T Hashimoto","year":"1996","unstructured":"Hashimoto T, Ebihara T, Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J Dermatol Sci. 1996;12(1):10\u20137. https:\/\/doi.org\/10.1016\/0923-1811(95)00449-1.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"272_CR289","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/1523-1747.ep12319025","volume":"109","author":"T Hashimoto","year":"1997","unstructured":"Hashimoto T, Kiyokawa C, Mori O, Miyasato M, Chidgey MA, Garrod DR, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol. 1997;109(2):127\u201331. https:\/\/doi.org\/10.1111\/1523-1747.ep12319025.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"272_CR290","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1034\/j.1600-0625.2000.009003224.x","volume":"9","author":"S Karpati","year":"2000","unstructured":"Karpati S, Amagai M, Liu WL, Dmochowski M, Hashimoto T, Horvath A. Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol. 2000;9(3):224\u20138. https:\/\/doi.org\/10.1034\/j.1600-0625.2000.009003224.x.","journal-title":"Exp Dermatol"},{"issue":"4","key":"272_CR291","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1365-2133.2006.07717.x","volume":"156","author":"LF Mentink","year":"2007","unstructured":"Mentink LF, de Jong MC, Kloosterhuis GJ, Zuiderveen J, Jonkman MF, Pas HH. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. Br J Dermatol. 2007;156(4):635\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07717.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"272_CR292","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.clindermatol.2011.01.014","volume":"29","author":"D Tsuruta","year":"2011","unstructured":"Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, et al. IgA pemphigus. Clin Dermatol. 2011;29(4):437\u201342. https:\/\/doi.org\/10.1016\/j.clindermatol.2011.01.014.","journal-title":"Clin Dermatol"},{"issue":"2","key":"272_CR293","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","volume":"110","author":"LS Chan","year":"1998","unstructured":"Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998;110(2):103\u20139. https:\/\/doi.org\/10.1046\/j.1523-1747.1998.00107.x.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"272_CR294","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.clml.2011.06.014","volume":"11","author":"P Szturz","year":"2011","unstructured":"Szturz P, Adam Z, Klincova M, Feit J, Krejci M, Pour L, et al. Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen. Clin Lymphoma Myeloma Leuk. 2011;11(6):517\u201320. https:\/\/doi.org\/10.1016\/j.clml.2011.06.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"272_CR295","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1006\/jaut.2000.0437","volume":"15","author":"A Kromminga","year":"2000","unstructured":"Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E, et al. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun. 2000;15(3):293\u2013300. https:\/\/doi.org\/10.1006\/jaut.2000.0437.","journal-title":"J Autoimmun"},{"issue":"2","key":"272_CR296","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0002-9440(10)64772-4","volume":"156","author":"H Schumann","year":"2000","unstructured":"Schumann H, Baetge J, Tasanen K, Wojnarowska F, Schacke H, Zillikens D, et al. The shed ectodomain of collagen XVII\/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol. 2000;156(2):685\u201395. https:\/\/doi.org\/10.1016\/S0002-9440(10)64772-4.","journal-title":"Am J Pathol"},{"issue":"5","key":"272_CR297","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/nu10050602","volume":"10","author":"T Reunala","year":"2018","unstructured":"Reunala T, Salmi T, Hervonen K, Kaukinen K, Collin P. Dermatitis herpetiformis: a common extraintestinal manifestation of coeliac disease. Nutrients. 2018;10(5):602. https:\/\/doi.org\/10.3390\/nu10050602.","journal-title":"Nutrients."},{"key":"272_CR298","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fimmu.2019.01290","volume":"10","author":"E Antiga","year":"2019","unstructured":"Antiga E, Maglie R, Quintarelli L, Verdelli A, Bonciani D, Bonciolini V, et al. Dermatitis herpetiformis: novel perspectives. Front Immunol. 2019;10:1290. https:\/\/doi.org\/10.3389\/fimmu.2019.01290.","journal-title":"Front Immunol"},{"issue":"5 Pt 2","key":"272_CR299","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/0190-9622(90)70125-2","volume":"22","author":"YZ Kuan","year":"1990","unstructured":"Kuan YZ, Chiou HT, Chang HC, Chan HL, Kuo TT. Intraepidermal neutrophilic IgA dermatosis. J Am Acad Dermatol. 1990;22(5 Pt 2):917\u20139. https:\/\/doi.org\/10.1016\/0190-9622(90)70125-2.","journal-title":"J Am Acad Dermatol"},{"key":"272_CR300","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-6-31","volume":"6","author":"K Csorba","year":"2011","unstructured":"Csorba K, Schmidt S, Florea F, Ishii N, Hashimoto T, Hertl M, et al. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases. Orphanet J Rare Dis. 2011;6:31. https:\/\/doi.org\/10.1186\/1750-1172-6-31.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"272_CR301","doi-asserted-by":"publisher","first-page":"adv00056","DOI":"10.2340\/00015555-3401","volume":"100","author":"T Salmi","year":"2020","unstructured":"Salmi T, Hervonen K. Current concepts of dermatitis herpetiformis. Acta Derm-Venereol. 2020;100(5):adv00056. https:\/\/doi.org\/10.2340\/00015555-3401.","journal-title":"Acta Derm-Venereol"},{"issue":"7","key":"272_CR302","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1468-3083.2012.04586.x","volume":"27","author":"G Borroni","year":"2013","unstructured":"Borroni G, Biagi F, Ciocca O, Vassallo C, Carugno A, Cananzi R, et al. IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients. J Eur Acad Dermatol Venereol. 2013;27(7):836\u201341. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04586.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"272_CR303","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1600-0560.2009.01472.x","volume":"37","author":"C Ko","year":"2010","unstructured":"Ko C, Colegio O, Moss J, McNiff J. Fibrillar IgA deposition in dermatitis herpetiformis\u2013an underreported pattern with potential clinical significance. J Cutan Pathol. 2010;37(4):475\u20137. https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01472.x.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"272_CR304","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1111\/jdv.16822","volume":"35","author":"F Ziberna","year":"2021","unstructured":"Ziberna F, Sblattero D, Lega S, Stefani C, Dal Ferro M, Marano F, et al. A novel quantitative ELISA as accurate and reproducible tool to detect epidermal transglutaminase antibodies in patients with Dermatitis Herpetiformis. J Eur Acad Dermatol Venereol. 2021;35(1):e78\u201380. https:\/\/doi.org\/10.1111\/jdv.16822.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"272_CR305","first-page":"115","volume":"10","author":"C Camisa","year":"1998","unstructured":"Camisa C, Warner M. Treatment of pemphigus. Dermatol Nurs. 1998;10(2):115\u20138, 123-31.","journal-title":"Dermatol Nurs."},{"issue":"8","key":"272_CR306","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/medicina57080818","volume":"57","author":"L Shin","year":"2021","unstructured":"Shin L, Gardner JT 2nd, Dao H Jr. Updates in the diagnosis and management of linear IgA disease: a systematic review. Medicina (Kaunas). 2021;57(8):818. https:\/\/doi.org\/10.3390\/medicina57080818.","journal-title":"Medicina (Kaunas)."},{"issue":"10","key":"272_CR307","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.dld.2022.06.023","volume":"54","author":"F Zingone","year":"2022","unstructured":"Zingone F, Maimaris S, Auricchio R, Caio G, Carroccio A, Elli L, et al. Guidelines of the Italian societies of gastroenterology on the diagnosis and management of coeliac disease and dermatitis herpetiformis. Dig Liver Dis. 2022;54(10):1304\u201319. https:\/\/doi.org\/10.1016\/j.dld.2022.06.023.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"272_CR308","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.iac.2012.04.004","volume":"32","author":"VA Venning","year":"2012","unstructured":"Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Immunol Allergy Clin North Am. 2012;32(2):245\u201353, vi. https:\/\/doi.org\/10.1016\/j.iac.2012.04.004.","journal-title":"Immunol Allergy Clin North Am."},{"key":"272_CR309","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jdcr.2021.12.030","volume":"21","author":"LK Herlin","year":"2022","unstructured":"Herlin LK, Deleuran M, Pallesen K, Bregnhoj A. Combined dapsone and sulfapyridine for the treatment of therapy-resistant linear IgA bullous dermatosis: two case reports. JAAD Case Rep. 2022;21:119\u201322. https:\/\/doi.org\/10.1016\/j.jdcr.2021.12.030.","journal-title":"JAAD Case Rep"},{"issue":"12","key":"272_CR310","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/ddg.15232_g","volume":"21","author":"JJ Lluch-Galcera","year":"2023","unstructured":"Lluch-Galcera JJ, Alcoverro C, Prat E, Martinez-Molina M, Bielsa I, Quer A, et al. Refraktarer IgA-Pemphigus erfolgreich mit Adalimumab als Monotherapie behandelt. J Dtsch Dermatol Ges. 2023;21(12):1560\u20132. https:\/\/doi.org\/10.1111\/ddg.15232_g.","journal-title":"J Dtsch Dermatol Ges"},{"key":"272_CR311","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","volume":"10","author":"C Kaegi","year":"2019","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. https:\/\/doi.org\/10.3389\/fimmu.2019.01990.","journal-title":"Front Immunol"},{"issue":"1","key":"272_CR312","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1684\/ejd.2007.0323","volume":"18","author":"S Marakli","year":"2008","unstructured":"Marakli S, Uzun S, Ozbek S, Tuncer I. Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. Eur J Dermatol. 2008;18(1):88\u20139. https:\/\/doi.org\/10.1684\/ejd.2007.0323.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"272_CR313","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2005.02.051","volume":"53","author":"SM Howell","year":"2005","unstructured":"Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005;53(3):541\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2005.02.051.","journal-title":"J Am Acad Dermatol"},{"key":"272_CR314","doi-asserted-by":"publisher","first-page":"863095","DOI":"10.3389\/fimmu.2022.863095","volume":"13","author":"M Maho-Vaillant","year":"2022","unstructured":"Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13:863095. https:\/\/doi.org\/10.3389\/fimmu.2022.863095.","journal-title":"Front Immunol"},{"issue":"11","key":"272_CR315","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/jdv.19489","volume":"37","author":"E Antiga","year":"2023","unstructured":"Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, et al. Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023;37(11):2378\u20139. https:\/\/doi.org\/10.1111\/jdv.19489.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"272_CR316","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamadermatol.2018.5536","volume":"155","author":"A Wald","year":"2019","unstructured":"Wald A, Schmidt E, Toberer F, Gutschalk A, Rentzsch K, Enk AH, et al. Overlap of bullous, anti-laminin-332, and anti-p200 Pemphigoid with concomitant anti-contactin-1-positive inflammatory polyneuropathy treated with intravenous immunoglobulins as a manifestation of epitope spreading. JAMA Dermatol. 2019;155(5):631\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5536.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"272_CR317","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.jid.2024.02.029","volume":"144","author":"Y Ruan","year":"2024","unstructured":"Ruan Y, Xu C, Zhang T, Zhu L, Wang H, Wang J, et al. Single-cell profiling unveils the inflammatory heterogeneity within cutaneous lesions of bullous pemphigoid. J Invest Dermatol. 2024;144(10):2176\u20132186 e6. https:\/\/doi.org\/10.1016\/j.jid.2024.02.029.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"272_CR318","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jaci.2024.09.030","volume":"155","author":"S Shengxian","year":"2024","unstructured":"Shengxian S, Hui F, Xia L, Yifan Z, Xin T, Haijun M, et al. Eosinophil extracellular traps drive T follicular helper cell differentiation via VIRMA-dependent MAF stabilization in bullous pemphigoid. J Allergy Clin Immunol. 2024;155(4):1357\u201370. https:\/\/doi.org\/10.1016\/j.jaci.2024.09.030.","journal-title":"J Allergy Clin Immunol."},{"key":"272_CR319","doi-asserted-by":"publisher","unstructured":"Yutong R, Xueting P, Yumin X, Yale L. IL-24 for bullous pemphigoid severity: a case-control study. J Eur Acad Dermatol Venereol. 2024;(0)\u00a0https:\/\/doi.org\/10.1111\/jdv.20467","DOI":"10.1111\/jdv.20467"},{"issue":"1\u20132","key":"272_CR320","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jim.2012.05.007","volume":"382","author":"J Damoiseaux","year":"2012","unstructured":"Damoiseaux J, van Rijsingen M, Warnemunde N, Dahnrich C, Fechner K, Tervaert JW. Autoantibody detection in bullous pemphigoid: clinical evaluation of the EUROPLUS Dermatology Mosaic. J Immunol Methods. 2012;382(1\u20132):76\u201380. https:\/\/doi.org\/10.1016\/j.jim.2012.05.007.","journal-title":"J Immunol Methods"},{"issue":"1","key":"272_CR321","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/jcm12010328","volume":"12","author":"M Carlo Alberto","year":"2023","unstructured":"Carlo Alberto M, Nicoletta C, Giovanni G, Caterina F, Gino Antonio V, Angelo Valerio M. The intriguing links between psoriasis and bullous pemphigoid. J Clin Med. 2023;12(1):328. https:\/\/doi.org\/10.3390\/jcm12010328.","journal-title":"J Clin Med."},{"key":"272_CR322","doi-asserted-by":"publisher","first-page":"1196999","DOI":"10.3389\/fimmu.2023.1196999","volume":"14","author":"J Huttelmaier","year":"2023","unstructured":"Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol. 2023;14:1196999. https:\/\/doi.org\/10.3389\/fimmu.2023.1196999.","journal-title":"Front Immunol"},{"issue":"10","key":"272_CR323","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"BM Iain","year":"2021","unstructured":"Iain BM, Ellen MG. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680\u20136. https:\/\/doi.org\/10.1038\/s41577-021-00603-1.","journal-title":"Nat Rev Immunol."},{"issue":"2","key":"272_CR324","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jdermsci.2021.11.011","volume":"105","author":"T Ramcke","year":"2022","unstructured":"Ramcke T, Vicari E, Bolduan V, Enk A, Hadaschik E. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP. J Dermatol Sci. 2022;105(2):72\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.11.011.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"272_CR325","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/dermatopathology9030034","volume":"9","author":"Y Matsushima","year":"2022","unstructured":"Matsushima Y, Kitano M, Hayashi D, Goto H, Mine M, Yokoe T, et al. A case of IgG and IgA anti-laminin-332 antibody-positive mucous membrane pemphigoid with IgG and IgA anti-envoplakin and anti-periplakin antibodies. Dermatopathology (Basel). 2022;9(3):287\u201391. https:\/\/doi.org\/10.3390\/dermatopathology9030034.","journal-title":"Dermatopathology (Basel)"},{"issue":"9","key":"272_CR326","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1111\/1346-8138.16008","volume":"48","author":"H Kawashima","year":"2021","unstructured":"Kawashima H, Kageji R, Hida Y, Goto T, Ishii N, Hashimoto T. Case of pemphigoid with antibodies to BP180 C-terminal domain and alpha3 subunit of laminin-332 associated with chronic graft-versus-host disease. J Dermatol. 2021;48(9):e447\u20138. https:\/\/doi.org\/10.1111\/1346-8138.16008.","journal-title":"J Dermatol"},{"issue":"5","key":"272_CR327","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/1346-8138.15833","volume":"48","author":"Y Shimoda-Komatsu","year":"2021","unstructured":"Shimoda-Komatsu Y, Fukui K, Yamazaki Y, Ohyama M. Development of pemphigus foliaceus in a mucous membrane pemphigoid patient: an insight into possible mechanism eliciting a distinct autoimmune bullous disease in a rare anti-basement membrane autoimmunity. J Dermatol. 2021;48(5):710\u20134. https:\/\/doi.org\/10.1111\/1346-8138.15833.","journal-title":"J Dermatol"},{"issue":"5","key":"272_CR328","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaad.2016.11.002","volume":"76","author":"N van Beek","year":"2017","unstructured":"van Beek N, Dahnrich C, Johannsen N, Lemcke S, Goletz S, Hubner F, et al. Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol. 2017;76(5):889\u2013894 e5. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.002.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"272_CR329","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.jaad.2020.01.049","volume":"83","author":"N van Beek","year":"2020","unstructured":"van Beek N, Kruger S, Fuhrmann T, Lemcke S, Goletz S, Probst C, et al. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. J Am Acad Dermatol. 2020;83(5):1315\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.049.","journal-title":"J Am Acad Dermatol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:17:42Z","timestamp":1747300662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":329,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00272-9","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants in this study were derived from the autoimmune bullous disease cohort of West China Hospital (AIBD-WCH). The AIBD-WCH was established in 2016, which was approved by the biomedical research ethics committee of West China Hospital of Sichuan University (Approval number: 2017\u2013241). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}